WO2013184794A2 - Peripheral kappa receptor agonists for reducing pain and inflammation - Google Patents
Peripheral kappa receptor agonists for reducing pain and inflammation Download PDFInfo
- Publication number
- WO2013184794A2 WO2013184794A2 PCT/US2013/044302 US2013044302W WO2013184794A2 WO 2013184794 A2 WO2013184794 A2 WO 2013184794A2 US 2013044302 W US2013044302 W US 2013044302W WO 2013184794 A2 WO2013184794 A2 WO 2013184794A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ring
- group
- inflammation
- peripherally
- alkyl
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 54
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 54
- 108020001588 κ-opioid receptors Proteins 0.000 title claims abstract description 18
- 102000048260 kappa Opioid Receptors Human genes 0.000 title claims abstract description 17
- 229940044601 receptor agonist Drugs 0.000 title abstract description 8
- 239000000018 receptor agonist Substances 0.000 title abstract description 8
- 208000002193 Pain Diseases 0.000 title description 48
- 230000036407 pain Effects 0.000 title description 47
- 230000002093 peripheral effect Effects 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 71
- 239000002632 kappa opiate receptor agonist Substances 0.000 claims abstract description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 47
- 102000004127 Cytokines Human genes 0.000 claims abstract description 28
- 108090000695 Cytokines Proteins 0.000 claims abstract description 28
- 229940126470 kappa opioid receptor agonist Drugs 0.000 claims abstract description 28
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 10
- 150000008574 D-amino acids Chemical class 0.000 claims abstract description 8
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 6
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 5
- 150000001408 amides Chemical class 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- -1 D-lNal Chemical compound 0.000 claims description 25
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 25
- 102000004889 Interleukin-6 Human genes 0.000 claims description 22
- 108090001005 Interleukin-6 Proteins 0.000 claims description 22
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 230000009467 reduction Effects 0.000 claims description 18
- 125000006413 ring segment Chemical group 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 17
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 238000009802 hysterectomy Methods 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 13
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- PECYZEOJVXMISF-UWTATZPHSA-N 3-amino-D-alanine Chemical compound NC[C@@H](N)C(O)=O PECYZEOJVXMISF-UWTATZPHSA-N 0.000 claims description 6
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 6
- 239000000730 antalgic agent Substances 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 5
- 108090001007 Interleukin-8 Proteins 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- XGZZHZMWIXFATA-UEZBDDGYSA-N nalfurafine Chemical group C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3N(C)C(=O)\C=C\C1=COC=C1)CN2CC1CC1 XGZZHZMWIXFATA-UEZBDDGYSA-N 0.000 claims description 5
- 229960000441 nalfurafine Drugs 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 102000000743 Interleukin-5 Human genes 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 108700012920 TNF Proteins 0.000 claims description 4
- JHLHNYVMZCADTC-LOSJGSFVSA-N asimadoline Chemical group C([C@@H](N(C)C(=O)C(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)N1CC[C@H](O)C1 JHLHNYVMZCADTC-LOSJGSFVSA-N 0.000 claims description 4
- FXHCFPUEIDRTMR-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid;chloride Chemical compound Cl.C1=CC=C2CNC(C(=O)O)CC2=C1 FXHCFPUEIDRTMR-UHFFFAOYSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 238000002357 laparoscopic surgery Methods 0.000 claims description 4
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 claims description 3
- 150000001204 N-oxides Chemical class 0.000 claims description 3
- 229950002202 asimadoline Drugs 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- VVDNQYDGDFYGMM-SSDOTTSWSA-N (2r)-2-amino-3-piperidin-4-ylpropanoic acid Chemical compound OC(=O)[C@H](N)CC1CCNCC1 VVDNQYDGDFYGMM-SSDOTTSWSA-N 0.000 claims description 2
- NPDBDJFLKKQMCM-BYPYZUCNSA-N (2r)-2-azaniumyl-3,3-dimethylbutanoate Chemical compound CC(C)(C)[C@@H]([NH3+])C([O-])=O NPDBDJFLKKQMCM-BYPYZUCNSA-N 0.000 claims description 2
- LPBSHGLDBQBSPI-RXMQYKEDSA-N (2r)-2-azaniumyl-4,4-dimethylpentanoate Chemical compound CC(C)(C)C[C@@H]([NH3+])C([O-])=O LPBSHGLDBQBSPI-RXMQYKEDSA-N 0.000 claims description 2
- JTTHKOPSMAVJFE-SECBINFHSA-N (2r)-2-azaniumyl-4-phenylbutanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CCC1=CC=CC=C1 JTTHKOPSMAVJFE-SECBINFHSA-N 0.000 claims description 2
- KHABBYNLBYZCKP-UHFFFAOYSA-N 4-aminopiperidin-1-ium-4-carboxylate Chemical compound OC(=O)C1(N)CCNCC1 KHABBYNLBYZCKP-UHFFFAOYSA-N 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 claims description 2
- 201000011275 Epicondylitis Diseases 0.000 claims description 2
- 206010019909 Hernia Diseases 0.000 claims description 2
- BGBGFGPRNXUSGX-LWOQYNTDSA-N N[C@@H](C(=O)O)CN1C(CCC1)N Chemical compound N[C@@H](C(=O)O)CN1C(CCC1)N BGBGFGPRNXUSGX-LWOQYNTDSA-N 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010034464 Periarthritis Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 208000002240 Tennis Elbow Diseases 0.000 claims description 2
- 208000004760 Tenosynovitis Diseases 0.000 claims description 2
- 238000007486 appendectomy Methods 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 238000002192 cholecystectomy Methods 0.000 claims description 2
- 238000012321 colectomy Methods 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 238000002052 colonoscopy Methods 0.000 claims description 2
- 238000010878 colorectal surgery Methods 0.000 claims description 2
- 238000002574 cystoscopy Methods 0.000 claims description 2
- 230000002357 endometrial effect Effects 0.000 claims description 2
- 238000013110 gastrectomy Methods 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 201000005111 ocular hyperemia Diseases 0.000 claims description 2
- 230000003349 osteoarthritic effect Effects 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 238000011471 prostatectomy Methods 0.000 claims description 2
- 238000002271 resection Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims description 2
- 238000010911 splenectomy Methods 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 238000009810 tubal ligation Methods 0.000 claims description 2
- 238000007879 vasectomy Methods 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 238000005299 abrasion Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 15
- 239000000902 placebo Substances 0.000 description 40
- 238000001356 surgical procedure Methods 0.000 description 37
- 229940068196 placebo Drugs 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 28
- 238000003556 assay Methods 0.000 description 25
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 22
- 229940100601 interleukin-6 Drugs 0.000 description 17
- 108010074051 C-Reactive Protein Proteins 0.000 description 13
- 102100032752 C-reactive protein Human genes 0.000 description 13
- 230000000202 analgesic effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 229960005181 morphine Drugs 0.000 description 11
- 208000004550 Postoperative Pain Diseases 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000004005 microsphere Substances 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 229930182832 D-phenylalanine Natural products 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000002756 mu opiate receptor agonist Substances 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229940127558 rescue medication Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NMDDZEVVQDPECF-ZCFIWIBFSA-N (2R)-2,7-diaminoheptanoic acid Chemical compound NCCCCC[C@@H](N)C(O)=O NMDDZEVVQDPECF-ZCFIWIBFSA-N 0.000 description 2
- IFPQOXNWLSRZKX-GSVOUGTGSA-N (2r)-2-amino-4-(diaminomethylideneamino)butanoic acid Chemical group OC(=O)[C@H](N)CCNC(N)=N IFPQOXNWLSRZKX-GSVOUGTGSA-N 0.000 description 2
- QUOGESRFPZDMMT-RXMQYKEDSA-N (2r)-2-amino-6-(diaminomethylideneamino)hexanoic acid Chemical group OC(=O)[C@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-RXMQYKEDSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 229930028154 D-arginine Natural products 0.000 description 2
- 229930182819 D-leucine Natural products 0.000 description 2
- LRQKBLKVPFOOQJ-RXMQYKEDSA-N D-norleucine Chemical compound CCCC[C@@H](N)C(O)=O LRQKBLKVPFOOQJ-RXMQYKEDSA-N 0.000 description 2
- 229930182820 D-proline Natural products 0.000 description 2
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000036741 Pruritus generalised Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexyl-acetic acid Natural products OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UJOQOPBFLFQOJJ-HXUWFJFHSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-methylhexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CCC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UJOQOPBFLFQOJJ-HXUWFJFHSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- DJSFYNINGIMKAG-FQJQBBMWSA-N (e)-n-[(4r,4as,7r,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-yl]-3-(furan-3-yl)-n-methylprop-2-enamide;hydron;chloride Chemical compound Cl.C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3N(C)C(=O)\C=C\C1=COC=C1)CN2CC1CC1 DJSFYNINGIMKAG-FQJQBBMWSA-N 0.000 description 1
- OKRURFWORCCNOU-UHFFFAOYSA-N 1,2-dihydroimidazole-3-carboximidamide Chemical class NC(=N)N1CNC=C1 OKRURFWORCCNOU-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000027502 Ankle fracture Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- 125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- 150000008541 D-alanines Chemical class 0.000 description 1
- 229930182845 D-isoleucine Natural products 0.000 description 1
- 229930182818 D-methionine Natural products 0.000 description 1
- 125000001711 D-phenylalanine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229930182822 D-threonine Natural products 0.000 description 1
- 229930182827 D-tryptophan Natural products 0.000 description 1
- 229930195709 D-tyrosine Natural products 0.000 description 1
- 229930182831 D-valine Natural products 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000854350 Enicospilus group Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000288904 Lemur Species 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- 241001602876 Nata Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000144958 Piaractus mesopotamicus Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010060875 Uraemic pruritus Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000020089 femoral neck fracture Diseases 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 238000001824 photoionisation detection Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Definitions
- the present invention relates to the prevention, inhibition or treatment of inflammation, especially inflammation resulting from surgical procedures or other bodily insult. More particularly, the invention relates to the administration of peripherally-restricted kappa opioid receptor agonists to reduce post-surgical inflammation.
- Non-narcotic analgesics such as the non-steroidal anti-inflammatory drugs
- NSAIDs have been used for the management and treatment of pain and inflammation.
- the NSAIDs e.g. ibuprofen
- unwanted side effects such as hepatotoxicity and ulcers and gastric bleeding due to Coxl activity.
- analgesics and antiinflammatory agents that are free of these side effects of NSAIDs.
- Morphine acts at the mu opioid receptor to produce its analgesic effects.
- US patent 5,965,701 to Junien et al. discloses kappa receptor agonists which have an affinity for the KOR at least 1,000 times their affinity for the mu opioid receptor and an ED 50 of not greater than about 0.5 mg/kg.
- US patents 7,402,564; 7,727,963 and 7,713,937 disclose synthetic peptide amides that are kappa opioid receptor ligands and exhibit low P450 CYP inhibition and low penetration into the brain.
- US patent 7,842,662 discloses dimeric forms of the synthetic peptide amides that retain their kappa receptor agonist properties.
- US patent application no.12/768,686 discloses the administration of the kappa opioid agonist synthetic peptide amides by intravenous, oral and topical routes.
- US patent application publication no. 2010/0075910 discloses the use of the kappa opioid agonist synthetic peptide amides for the treatment of inflammatory pain.
- the morphine- sparing effects of one such the kappa opioid agonist synthetic peptide amide, CR845, administered to women after laparoscopic-assisted hysterectomy has been reported (Menzaghi et al., 2010 13 th World Congress on Pain).
- CR845 In this reported Phase 2 clinical trial, subjects were administered a 15-minute intravenous infusion of 0.04 mg/kg CR845 or matching placebo following recovery from surgery and reaching a pain intensity baseline level of from 5 to 8 on a scale of zero to 11. Pain intensity was assessed up to 8 hours after the CR845 infusion or until morphine was administered by patient controlled analgesia. Morphine use was reduced by 32% over the first 16 hours post- infusion in CR845-treated patients versus placebo accompanied by a significant reduction in opioid side effects (vomiting, nausea and pruritis, i.e. itching) with no significant changes in clinical lab test results, vital signs, electrocardiograms, or Ramsey sedation scale assessment. CR845 was shown to be safe and well tolerated, and effective in reducing pain intensity when administered after surgery.
- Fig. 1 shows the design of the clinical trial described in Example 1.
- N Number of patients; VAS: visual analog pain scale; PACU: post anesthesia care unit; Opioid Rescue prn: Pro re nata - Opioid rescue "as needed.”
- Fig. 2 shows the relative levels of reduction of post-operative pain over the first
- SPID pain intensity difference
- Fig. 3 shows the relative levels of reduction of post-operative pain over the first
- Fig 4 shows the amounts of morphine (in milligrams) self administered by the patients in each group: placebo-placebo, placebo-CR845, CR845-placebo, and CR845-CR845 in the intervals: 2-4 hours, 4-12 hours and 12-24 hours post surgery.
- Fig. 5 shows the evaluations of pain relief as assessed by the patients themselves, demonstrating that pre-treatment with CR845 was consistently evaluated as very good or excellent by the highest percentage of patients.
- Fig. 6 shows the results of C-reactive protein assays in samples of patient serum taken pre surgery and at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
- Fig. 7 shows the results of IL-6 assays in samples of patient serum taken pre surgery and at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
- Fig. 8A shows the results of TNFa assays and Fig. 8B shows the results of IL- ⁇ assays in samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
- Fig. 9A shows the results of IL-2 assays
- Fig. 9B shows the results of IL-8 assays in samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
- Fig. 10A shows the results of IL-12 assays and Fig. 10B shows the results of
- GM-CSF assays in samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
- Fig. 11A shows the results of IL-6 assays and Fig. 11B shows the results of IL-7 assays in samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
- Fig. 12A shows the results of IL-4 assays and Fig. 12B shows the results of IFNy assays from samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving placebo or a single dose of CR845.
- Fig. 13A shows the results of IL-5 assays and Fig. 13B shows the results of IL-10 assays in samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
- Fig. 14 shows the results of IL-13 assays from samples of patient serum taken at
- Fig. 15 shows the incidence of treatment emergent adverse events (TEAEs) including nausea, vomiting, pruritus and generalized pruritus through 24 hours after first infusion of CR845 after laparoscopic hysterectomy in a Phase lib trial.
- TEAEs treatment emergent adverse events
- the present invention provides a method for reducing kappa opioid receptor-associated inflammation in a mammalian subject, wherein the method includes administering an effective amount of a peripherally-restricted kappa opioid receptor agonist to the subject.
- the inflammation is due to an inflammatory disease or condition. In another embodiment the inflammation is due to a medical procedure.
- the present invention provides a method for reducing kappa opioid receptor-associated inflammation in a mammalian subject, the method includes administering an effective amount of a peripherally-restricted kappa opioid receptor agonist and wherein the administering of the peripherally restricted kappa opioid receptor agonist causes a reduction in the level of one or more pro-inflammatory cytokines and/or the increase in an level of one or more anti-inflammatory cytokines in the blood of the subject.
- the pro-inflammatory cytokines are chosen from IL- ⁇ , IL-2, IL-4 IL-6, IL-7, IL-8, IL-12(p70), GM-CSF, TNFa and IFNy.
- the anti-inflammatory cytokines are chosen from IL-5, IL-10 and IL-13.
- the invention provides the first-in-man use of a non-narcotic kappa opioid receptor agonist analgesic used as a pretreatment prior to and/or during surgery to reduce pain and inflammation.
- the peripheral restriction of the kappa opioid receptor agonist analgesics of the invention provides the non-narcotic analgesic and anti-inflammatory properties due to action at peripheral kappa receptors and very limited penetration across the blood brain barrier, and therefore little or no action at the kappa receptors in the CNS and the brain.
- the present invention provides a method for reducing kappa opioid receptor- associated inflammation in a mammalian subject, the method comprising administering an effective amount of a peripherally restricted kappa opioid receptor agonist to the subject and thereby reducing the kappa opioid receptor-associated inflammation in the mammalian subject.
- the kappa opioid receptor-associated inflammation can be any inflammatory disease or condition including, but not limited to sinusitis, rheumatoid arthritis tenosynovitis, bursitis, tendonitis, lateral epicondylitis, adhesive capsulitis, osteomyelitis, osteoarthritic inflammation, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ocular inflammation, otitic inflammation or autoimmune inflammation.
- sinusitis rheumatoid arthritis tenosynovitis, bursitis, tendonitis, lateral epicondylitis, adhesive capsulitis, osteomyelitis, osteoarthritic inflammation, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ocular inflammation, otitic inflammation or autoimmune inflammation.
- IBD inflammatory bowel disease
- IBS irritable bowel syndrome
- ocular inflammation otitic inflammation or autoimmune inflammation.
- the present invention provides a method for reducing post medical procedure inflammation in a mammalian subject, the method comprising administering an effective amount of a peripherally restricted kappa opioid receptor agonist to the subject prior to the medical procedure that normally causes post- medical procedure inflammation and thereby reducing the post-medical procedure inflammation experienced by the subject.
- the subject can be a human patient, a non-human primate or any other mammal.
- the non-human primate can be any non-human primate such as, for instance an ape, gorilla, orangutan, lemur, monkey or chimpanzee.
- the non-primate mammal can be the non-primate mammal such as a pet or companion animal, e.g. a dog or a cat; a high-value mammal such as a thoroughbred horse, a show animal or a farm animal, such as a cow, a goat, a sheep or a pig.
- the invention provides a method for reducing patient need for morphine, such as for instance as judged by patient controlled analgesia (PCA) demand.
- PCA patient controlled analgesia
- the peripherally restricted kappa opioid receptor agonist useful in the practice of the present invention includes a peptide.
- the peptide can include any amino acid, such as for instance a natural amino acid, an L-amino acid, a D-amino acid, or a non- natural amino acid, such as for instance, and without limitation, D-Ala(cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), D-Ala(thienyl), D-Nle (i.e., D-norleucine) or (a-Me)D-Leu.
- the peptide includes at least four D-amino acids.
- the peripherally restricted kappa opioid receptor agonist includes a synthetic peptide amide having the formula I:
- the residue Xaai can be any of the following: (A)(A')D-Phe,
- residue Xaa 2 is selected from the group consisting of
- residue Xaa 3 is selected from the group consisting of
- residue Xaa 4 is selected from the group consisting of
- the linking group, W is selected from the group consisting of: Null, provided that when W is null, Y is N; -NH-(CH 2 )b- with b equal to zero, 1, 2, 3, 4, 5, or 6; and -NH-(CH 2 ) c -0- with c equal to 2, or 3, provided that Y is C.
- Y and Z are each independently C or N.
- Y and Z are each independently C or N, provided that when such ring moiety is a six, seven or eight-membered ring, Y and Z are separated by at least two ring atoms.
- ring heteroatoms in said ring moiety are N; wherein Y and Z are each independently C or N provided that when such ring moiety has a single ring heteroatom which is N, then such ring moiety is non-aromatic; the group, V is C -C alkyl, and e is zero or 1, wherein when e is zero, then V is null and and R 2 are directly bonded to the same or different ring atoms.
- R is selected from the group consisting of -H, -OH, halo, -CF 3 , -NH 2 , -COOH, C C 6 alkyl, CrC 6 alkoxy, amidino, CrC 6 alkyl-substituted amidino, aryl, optionally substituted heterocyclyl, Pro-amide, Pro, Gly, Ala, Val, Leu, He, Lys, Arg, Orn, Ser, Thr, -CN, -CONH 2 , -COR', -S0 2 R', -CONR'R", -NHCOR', OR' and S0 2 NR'R"; wherein said optionally substituted heterocyclyl is optionally singly or doubly substituted with substituents independently selected from the group consisting of CrC 6 alkyl, CrC 6 alkoxy, oxo, -OH, -CI, -F, -NH 2 , -N0 2
- Ri and R 2 taken together can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety which is bonded to a single ring atom of the Y and Z-containing ring moiety;
- Ri and R 2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4- to 8-membered heterocyclic ring moiety to form a spiro structure;
- Ri and R 2 taken together with two or more adjacent ring atoms of the Y and Z- containing ring moiety can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety; wherein each of said optionally substituted 4-, 5-, 6,-, 7-, 8- and 9-membered heterocyclic ring moieties comprising Ri and R 2 is optionally singly or doubly substituted with substituents independently selected from the group consisting of C -C alkyl, C -C alkoxy, optionally substituted phenyl, oxo, -OH, -CI, -F, -NH 2 , -N0 2 , -CN, -COOH, and amidino.
- the post-medical procedure inflammation is due to a medical procedure selected from the following procedures: appendectomy, open colorectal surgery, hernia repair, prostatectomy, colonic resection, gastrectomy, splenectomy, colectomy, colostomy, pelvic laparoscopy, tubal ligation, hysterectomy, vasectomy, cholecystectomy, colonoscopy, cystoscopy, hysteroscopy, cervical and endometrial biopsy.
- post-medical procedure pain and inflammation is used interchangeably with the term "post-surgical” pain and inflammation in this specification.
- the post-medical procedure inflammation may be due to an orthopedic procedure, such as for instance knee or shoulder arthroscopy, knee joint and hip joint replacement, carpel tunnel release, anterior cruciate ligament reconstruction, repair of femoral neck or ankle fracture, meniscectomy and laminectomy, to name but a few.
- Other orthopedic procedures addressable by the present invention will be immediately apparent to clinicians, surgeons and those of skill in the art.
- D-isomer of an amino acid is specified by the prefix "D-" as in "D-Phe” which represents D-phenylalanine, the D-isomer of phenylalanine.
- L-isomer is specified by the prefix "L-" as in “L-Phe.”
- D-Arg represents D-arginine
- D-Har represents D-homoarginine, which has a side chain one methylene group longer than D-Arg
- D-Nar represents D-norarginine, which has a side chain one methylene group shorter than D- Arg.
- D-Leu means D-leucine
- D-Nle means D-norleucine
- D-Hle represents D- homoleucine
- D-Ala means D-alanine
- D-Tyr means D-tyrosine
- D-Trp means D-tryptophan
- D-Tic means D-l,2,3,4-tetrahydroisoquinoline-3carboxylic acid
- D-Val means D-valine and D-Met means D-methionine.
- D-Pro means D-proline
- Pro-amide means the D- or L- form of proline amide.
- D-Pro amide represents D-proline with an amide formed at its carboxy moiety wherein the amide nitrogen may be alkyl substituted, as in -NR a R b , wherein R a and R b are each independently a Ci-C6 alkyl group, or one of R a and R is -H.
- Gly means glycine
- D-Ile means D-isoleucine
- D-Ser means D-serine
- D-Thr means D-threonine.
- (E)D-Ala means the D- isomer of alanine which is substituted by the substituent (E) on the ⁇ -carbon.
- substituent (E) groups include tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, furyl, pyridyl, thienyl, thiazolyl and benzothienyl.
- cyclopentyl-D-Ala means the D-isomer of alanine which is substituted by cyclopentyl on the ⁇ -carbon.
- D-Ala(2-thienyl) and (2- thienyl)D-Ala are interchangeable and both mean the D-isomer of alanine substituted at the ⁇ - carbon with thienyl that is attached at the 2- ring position.
- D-Nal means the D-isomer of alanine substituted by naphthyl on the ⁇ -carbon.
- D-2Nal means naphthyl substituted D-alanine wherein the attachment to naphthalene is at the 2-position on the ring structure and
- D-lNal means naphthyl- substituted D- alanine wherein the attachment to naphthalene is at the 1-position on the ring structure.
- (A)( A')D-Phe D-phenylalanine substituted on the phenyl ring with one or two substituents independently chosen from halo, nitro, methyl, halomethyl (such as, for example, trifluoromethyl), perhalomethyl, cyano and carboxamide.
- D-(4-F)Phe D- phenylalanine which is fluoro-substituted in the 4-position of the phenyl ring.
- D-(2-F)Phe D-phenylalanine which is fluoro-substituted in the 2-position of the phenyl ring.
- D-(4- Cl)Phe D-phenylalanine which is chloro substituted in the 4- phenyl ring position.
- (a-Me)D-Phe D-phenylalanine which is methyl substituted at the alpha carbon.
- (a-Me)D-Leu D-leucine which is methyl substituted at the alpha carbon.
- the designations (B) 2 D-Arg, (B) 2 D-Nar, and (B) 2 D-Har represent D-arginine, D- norarginine and D-homoarginine, respectively, each having two substituent (B) groups on the side chain.
- D-Lys means D-lysine and D-Hlys means D-homolysine.
- s-(B)D- Lys, and s-(B) 2 -D-Lys represent D-homolysine and D-lysine each having the side chain amino group substituted with one or two substituent (B) groups, as indicated.
- D-Orn means D-ornithine and 5-(B)a-(B')D-Orn means D-ornithine substituted with ( ⁇ ') at the alpha carbon and substituted with (B) at the side chain ⁇ -amino group.
- D-Dap means D-2,3-diaminopropionic acid.
- D-Dbu represents the D-isomer of alpha, gamma-diamino butyric acid and (B) 2 D-Dbu represents alpha, gamma-diamino butyric acid which is substituted with two substituent (B) groups at the gamma amino group.
- each of the (B) groups of such doubly substituted residues are independently chosen from H- and C 1 -C 4 -alkyl.
- D-Amf means D-(NH 2 CH 2 -)Phe, i.e., the D- isomer of phenylalanine substituted with aminomethyl on its phenyl ring and D-4Amf represents the particular D-Amf in which the aminomethyl is attached at the 4- position of the ring.
- D-Gmf means D-Amf(amidino) which represents D-Phe wherein the phenyl ring is substituted with -CH 2 NHC(NH)NH 2 .
- Amd represents amidino, -C(NH)NH 2
- the designations (Amd)D-Amf and D-Amf(Amd) are also interchangeably used for D-Gmf.
- the designations Ily and lor are respectively used to mean isopropyl Lys and isopropyl Orn, wherein the side chain amino group is alkylated with an isopropyl group.
- Alkyl means an alkane radical which can be a straight, branched, and cyclic alkyl group such as, but not limited to, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, t-butyl, sec-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, cyclohexylethyl.
- i to alkyl refers to alkyl groups having between one and eight carbon atoms.
- CrC 6 alkyl refers to alkyl groups having between one and six carbon atoms.
- C C 4 alkyl refers to alkyl groups having between one and four carbon atoms.
- lower alkyl is meant C C 6 alkyl.
- Me, Et, Pr, Ipr, Bu, and Pn are interchangeably used to represent the common alkyl groups: methyl, ethyl, propyl, isopropyl, butyl, and pentyl, respectively.
- linkage for an alkyl group is typically at one end of an alkyl chain, the linkage may be elsewhere in the chain, e.g. 3-pentyl which may also be referred to as ethylpropyl, or 1-ethylprop- l-yl.
- Alkyl-substituted such as i to C 6 alkyl- substituted amidino, indicates that the relevant moiety is substituted with one or more alkyl groups.
- a specified moiety is null
- the moiety is absent and if such moiety is indicated to be attached to two other moieties, such two other moieties are connected by one covalent bond.
- a connecting moiety is shown herein as attached to a ring at any position on the ring, and attached to two other moieties, such as R and R 2 , in the case where the connecting moiety is specified to be null, then the 3 ⁇ 4 and R 2 moieties can each be independently attached to any position on the ring.
- heterocycle refers to a ring or ring moiety having at least one non-carbon ring atom, also called a heteroatom, which can be a nitrogen atom, a sulfur atom, or an oxygen atom.
- a ring is specified as having a certain number of members, the number defines the number of ring atoms without reference to any substituents or hydrogen atoms bonded to the ring atoms.
- Heterocycles, heterocyclic rings and heterocyclyl moieties can include multiple heteroatoms independently selected from nitrogen, sulfur, or oxygen atom in the ring. Rings can be substituted at any available position. For example, but without limitation, 6- and 7-membered rings are often substituted in the 4- ring position and 5-membered rings are commonly substituted in the 3- position, wherein the ring is attached to the peptide amide chain at the 1-ring position.
- saturated means an absence of double or triple bonds and the use of the term in connection with rings describes rings having no double or triple bonds within the ring, but does not preclude double or triple bonds from being present in substituents attached to the ring.
- non-aromatic in the context of a particular ring refers to an absence of aromaticity in that ring, but does not preclude the presence of double bonds within the ring, including double bonds which are part of an aromatic ring fused to the ring in question.
- a ring atom of a saturated heterocyclic ring moiety precluded from being double-bonded to a non- ring atom, such as for instance a ring sulfur atom being double-bonded to an oxygen atom substituent.
- heterocycles, heterocyclic rings and heterocyclyl moieties also include saturated, partially unsaturated and hetero aromatic rings and fused bicyclic ring structures unless otherwise specified.
- a heterocycle, heterocyclic ring or heterocyclyl moiety can be fused to a second ring, which can be a saturated, partially unsaturated, or aromatic ring, which ring can be a heterocycle or a carbocycle.
- two substituents can be optionally taken together to form an additional ring. Rings may be substituted at any available position.
- a heterocycle, heterocyclic ring and heterocyclyl moiety can, where indicted, be optionally substituted at one or more ring positions with one or more independently selected substituents, such as for instance, C -C alkyl, C 3 -C8 cycloalkyl, C -C alkoxy, halo Ci-C6 alkyl, optionally substituted phenyl, aryl, heterocyclyl, oxo, -OH, -CI, -F, -NH 2 , -N0 2 , -CN, -COOH and amidino.
- Suitable optional substituents of the phenyl substituent include for instance, but without limitation, one or more groups selected from C C 3 alkyl, C C 3 alkoxy, halo C C 3 alkyl, oxo, -OH, -CI, -F, -NH 2 , -N0 2 , -CN, -COOH and amidino.
- D-Phe and substituted D-Phe are examples of a suitable amino acid for residue
- the phenyl ring can be substituted at any of the 2-, 3- and/or 4-positions. Particular examples of permitted substitutions include, for instance, chlorine or fluorine at the 2- or 4- positions. Also the alpha-carbon atom may be methylated. Other equivalent residues which represent conservative changes to D-Phe can also be used. These include D-Ala(cyclo- pentyl), D-Ala(thienyl), D-Tyr and D-Tic. The residue at the second position, Xaa 2 can also be D-Phe or substituted D-Phe with such substitutions including a substituent on the 4-position carbon of the phenyl ring, or on both the 3- and 4-positions.
- Xaa 2 can be D-Trp, D-Tyr or D-alanine substituted by naphthyl.
- the third position residue, Xaa 3 can be any non- polar amino acid residue, such as for instance, D-Nle, D-Leu, (a-Me)D-Leu, D-Hle, D-Met or D- Val.
- D-Ala(cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) or D-Phe can also be used as Xaa 3 .
- the fourth position residue Xaa 4 can be any positively charged amino acid residue, such as for instance, D-Arg and D-Har, which can be optionally substituted with lower alkyl groups, such as one or two ethyl groups.
- D-Nar and any other equivalent residues can be used, such as, for instance, D-Lys or D-Orn (either of which can be co-amino group alkylated, for example by methyl or isopropyl groups, or methylated at the cc-carbon group).
- D-Dbu, D-4-Amf (which can be optionally substituted with amidino), and D- Hlys are also suitable amino acids at this position.
- Compounds of the invention contain one or more chiral centers, each of which has two possible three-dimensional spatial arrangements (configurations) of the four substituents around the central carbon atom. These are known as “stereoisomers”, and more specifically as “enantiomers” (all chiral centers inverted) or “diastereoisomers” (two or more chiral centers, at least one chiral center remaining the same).
- the amino acids which make up the tetrapeptide backbone, XaaiXaa 2 Xaa 3 Xaa 4 are specified to be D- amino acids i.e., the opposite configuration to those generally found in mammals.
- references to stereoisomers of the synthetic peptide amides of the invention in this specification relate to chiral centers other than the alpha carbons of the D-amino acids which make up Xaai-Xaa 4 .
- stereoisomers of synthetic peptide amides that are embodiments of the invention wherein each of XaarXaa 4 are specified to be D-amino acids do not include L- amino acids or racemic mixtures of the amino acids at these positions.
- reference to racemates herein concerns a center other than the alpha carbons of the D-amino acids which make up Xaai-Xaa 4 .
- Chiral centers in the synthetic peptide amides of the invention for which a stereoisomer may take either the R or S configuration include chiral centers in the moiety attached to the carboxy-terminus of Xaa 4 , and also chiral centers in any amino acid side chain substituents of Xaai-Xaa 4 .
- a "effective amount” or “sufficient amount” of the peripherally- restricted kappa receptor agonists of the invention such as the synthetic peptide amides refers to an amount of the compound as described herein that may be therapeutically effective to inhibit, prevent, or treat a symptom of a particular disease, disorder, condition, or side effect.
- a "reduced dose” of a mu opioid agonist analgesic compound refers to a dose which when used in combination with a kappa opioid agonist, such as a synthetic peptide amide of the invention, is lower than would be ordinarily provided to a particular patient, for the purpose of reducing one or more side effects of the compound.
- the dose reduction can be chosen such that the decrease in the analgesic or other therapeutic effect of the compound is an acceptable compromise in view of the reduced side effect(s), where the decrease in analgesic or other therapeutic effects of the mu opioid agonist analgesic are wholly or at least partially offset by the analgesic or other therapeutic effect of the synthetic peptide amide of other peripherally- restricted kappa receptor agonist of the invention.
- Co-administration of a mu opioid agonist analgesic compound with a synthetic peptide amide or other peripherally-restricted kappa receptor agonist of the invention also permits incorporation of a reduced dose of the peripherally-restricted kappa receptor agonist or synthetic peptide amide and/or the mu opioid agonist analgesic compound to achieve the same therapeutic effect as a higher dose of the synthetic peptide amide/other peripherally-restricted kappa receptor agonist or the mu opioid agonist analgesic compound if administered alone.
- pharmaceutically acceptable refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without severe toxicity, irritation, allergic response, or other complications, commensurate with a benefit-to-risk ratio that is reasonable for the medical condition being treated.
- dosage unit refers to a physically discrete unit suited as unitary dosages for a particular individual or condition to be treated.
- Each unit may contain a predetermined quantity of active synthetic peptide amide or other peripherally-restricted kappa receptor agonist compound(s) calculated to produce the desired therapeutic effect(s), optionally in association with a pharmaceutical carrier.
- the specification for the dosage unit forms may be dictated by (a) the unique characteristics of the active compound or compounds, and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such active compound or compounds.
- the dosage unit is often expressed as weight of compound per unit body weight, for instance, in milligrams of compound per kilogram of body weight of the subject or patient (mg/kg).
- the dosage can be expressed as the amount of the compound per unit body weight per unit time, (mg/kg/day) in a particular dosage regimen.
- the dosage can be expressed as the amount of compound per unit body surface area (mg/m ) or per unit body surface area per unit time
- the dosage can be expressed in a manner that is conventional for that formulation, e.g., a one-half inch ribbon of ointment applied to the eye, where the concentration of compound in the formulation is expressed as a percentage of the formulation.
- a "pharmaceutically acceptable salt” refers to a derivative of a compound wherein the parent compound is modified by making an acid or a base salt thereof.
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric acids and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic acids, and the like.
- inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric acids and the like
- organic acids such as acetic, propionic, succinic, glycolic, stearic,
- physiologically acceptable salts are prepared by methods known in the art, e.g., by dissolving the free amine bases with an excess of the acid in aqueous alcohol, or neutralizing a free carboxylic acid with an alkali metal base such as a hydroxide, or with an amine.
- a pharmaceutically acceptable salt of a synthetic peptide amide or other peripherally-restricted kappa receptor agonist can be formed from any such peptide amide having either acidic, basic or both functional groups.
- a peptide amide having a carboxylic acid group may in the presence of a pharmaceutically suitable base, form a carboxylate anion paired with a cation such as a sodium or potassium cation.
- a peptide amide having an amine functional group may, in the presence of a pharmaceutically suitable acid such as HC1, form a salt.
- An example of a pharmaceutically acceptable solvate of a synthetic peptide amide or other peripherally-restricted kappa receptor agonist is a combination of a synthetic peptide amide or other peripherally-restricted kappa receptor agonist with solvent molecules which yields a complex of such solvent molecules in association with the synthetic peptide amide or other peripherally-restricted kappa receptor agonist.
- Combinations of a drug and propylene glycol (1,2-propanediol) have been used to form pharmaceutical drug solvates. See for example U.S. patent No. 3,970,651.
- Other suitable solvates are hydrates of drug compounds.
- Such hydrates include hydrates which either have comparable activity or hydrates which are converted back to the active compound following administration.
- a pharmaceutically acceptable N-oxide of a synthetic peptide amide or other peripherally-restricted kappa receptor agonist is such a compound that contains an amine group wherein the nitrogen of the amine is bonded to an oxygen atom.
- a pharmaceutically acceptable crystalline, isomorphic crystalline or amorphous form of a synthetic peptide amide or other peripherally-restricted kappa receptor agonist of the invention can be any crystalline or non-crystalline form of a pharmaceutically acceptable acidic, basic, zwitterionic, salt, hydrate or any other suitably stable, physiologically compatible form of the synthetic peptide amide or other peripherally-restricted kappa receptor agonist according to the invention.
- the synthetic peptide amides or other peripherally-restricted kappa receptor agonists of the invention can be incorporated into pharmaceutical compositions.
- the compositions can include an effective amount of the synthetic peptide amide or other peripherally-restricted kappa receptor agonist in a pharmaceutically acceptable diluent, excipient or carrier.
- Conventional excipients, carriers and/or diluents for use in pharmaceutical compositions are generally inert and make up the bulk of the preparation.
- the present invention provides a method for reducing post medical procedure pain, post medical procedure inflammation, or both in a mammalian subject, the method comprising administering an effective amount of a peripherally restricted kappa opioid receptor agonist to the subject prior to the medical procedure that normally causes post- medical procedure pain, post-medical procedure inflammation, or both and thereby reducing the post-medical procedure pain and/or the post-medical procedure inflammation experienced by the subject; wherein the peripherally restricted kappa opioid receptor agonist has the structure of formula I:
- Ri-(V) e -R 2 Formula I wherein the Y and Z-containing ring moiety is a six or seven membered ring having a single ring heteroatom and e is zero, then R is not -OH, and R and R 2 are not both -H.
- RiR 2 is attached to a ring atom other than Z; and when e is zero, then R and R 2 are not both
- XaaiXaa 2 of formula I is D-Phe-D-Phe
- Xaa 3 is D-Leu or D-Nle
- Xaa 4 is selected from the group consisting of (B) 2 D-Arg, D-Lys, (B) 2 D-Har, D-Dap, ⁇ - (B)D-Lys, s-(B) 2 -D-Lys, D-Amf, amidino-D-Amf, y-(B) 2 D-Dbu and 5-(B) 2 a-(B')D-Orn.
- Xaa 4 is selected from D-Lys, (B) 2 D-Har, s-(B)D-Lys and s-(B) 2 -D-Lys.
- W is null
- Y is N
- Z is C.
- the Y and Z- containing ring moiety is a six-membered saturated ring comprising a single ring heteroatom.
- the groups R and R 2 taken together with zero, one or two ring atoms of the Y and Z-containing ring moiety comprise a monocyclic or bicyclic 4-9 membered heterocyclic ring moiety.
- the moiety e is zero and the groups R and R 2 are each bonded directly to the same ring atom, R x is H, OH, -NH 2 , -COOH, -CH 2 COOH, C C 3 alkyl, amidino, C C 3 alkyl-substituted amidino, dihydroimidazole, D-Pro, D-Pro amide, or CONH 2 and R 2 is H, -COOH, or CrC 3 alkyl.
- Xaa ⁇ aa 2 is D-Phe-D-Phe
- Xaa 3 is D-Leu or D-Nle
- Xaa 4 is selected from (B) 2 D-Arg, D-Lys, (B) 2 D-Har, ⁇ -( ⁇ ) ⁇ - ⁇ , D-Dap, s-(B)D-Lys, s-(B) 2 -D-Lys, D-Amf, amidino-D-Amf, y-(B) 2 D-Dbu and 5-(B) 2 a-(B')D-Orn.
- Asimadoline a selective, non-peptidic kappa-opioid receptor agonists is also useful I methods according to the present invention for pretreatment prior to surgery in order to reduce post-surgical pain and inflammation.
- Asimadoline has the diarylacetamide structure shown below:
- Nalfurafine (also known as AC-820, TRK-820) is a kappa opioid receptor agonist marketed as a treatment for uremic pruritus in hemodialysis patients. Nalfurafine is another kappa opioid receptor agonist useful according to the present invention for pretreatment prior to surgery in order to reduce post-surgical pain and inflammation.
- Nalfurafine is (2E)-N-[(5a,6P)-17-(cyclopropylmethyl)- 3,14-dihydroxy- 4,5- epoxymorphinan- 6-yl]- 3-(3-furyl)- N-methylacrylamide, and has the following chemical structure:
- the method further includes administering another dose of the peripherally restricted kappa opioid receptor agonist to the subject during or after the medical procedure.
- the relief from post- medical procedure pain is such that the subject self administers little or no patient controlled analgesia (PCA) after surgery and/or during recovery.
- PCA patient controlled analgesia
- the relief from post- medical procedure inflammation is accompanied by relief from pruritis during the period of recovery from the medical procedure.
- the peripherally restricted kappa opioid receptor agonist useful in the practice of the present invention is a non-narcotic analgesic.
- the peripherally restricted kappa opioid receptor agonist is administered by a route of injection selected from the group consisting of subcutaneous injection, intravenous injection, intraperitoneal injection, intraarticular injection, intramuscular injection or intra-ocular injection.
- Inflammation is a complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. Inflammation can be acute or chronic, and is often characterized by fever in mammals. Inflammation is a protective response to an inflammatory stimulus and initiates wound-healing processes.
- Interleukin-6 IL6
- the level of C-reactive protein can be determined by commercially available ELISA assays. IL6 and CRP have been as clinical markers of inflammation, see for instance Esme et al. (2011) Effects of Flurbiprofen on CRP, TNF- , IL6 and Postoperative Pain of Thoractomy; Int. J. Med. Sci. vol. 8£3): pp 216-221.
- Cytokine Assays are used to measure IL6 in 96-well MULTI-ARRAY ® or MULTISPOT ® plates.
- the assays employ a sandwich immunoassay format where capture antibodies are coated in a single spot, or in a patterned array, on the bottom of the wells of a MULTIARRAY ® or MULTI-SPOT ® plate.
- the sample and a solution containing the labeled detection antibody- anti-IL6 antibody labeled with an electrochemiluminescent compound, MSD SULFO-TAGTM label- are added over the course of one or more incubation periods.
- the IL6 in the sample binds to capture antibody immobilized on the working electrode surface; recruitment of the labeled detection antibody by bound cytokine completes the sandwich.
- the user adds an MSD read buffer that provides the appropriate chemical environment for electrochemiluminescence and loads the plate into an MSD SECTOR ® instrument for analysis. Inside the SECTOR ® instrument, a voltage applied to the plate electrodes causes the labels bound to the electrode surface to emit light. The instrument measures intensity of emitted light to provide a quantitative measure of IL6 present in the sample.
- EXAMPLE 1 First in man clinical trial of a peripherally-restricted non-narcotic kappa receptor agonist
- This trial was a phase 2 multi-center, double-randomized, double-blind, placebo- controlled study was conducted to evaluate the analgesic efficacy and safety of intravenous CR845 dosed preoperatively and postoperatively in patients undergoing a laparoscopic hysterectomy.
- the trial was conducted under an investigational new drug application (IND) filed with the US Food and Drug Administration (FDA).
- IND investigational new drug application
- FDA US Food and Drug Administration
- CR845 is a peripherally-restricted kappa-opioid receptor agonist, in Phase 2 of clinical development for the treatment of acute pain.
- CR845 has been shown to have analgesic and morphine-sparing effects in a proof of concept clinical study when administered after surgery (single intravenous dose) (Menzaghi et al., IASP 2010).
- CR845 appeared to be better tolerated in comparison to other known kappa agonists, likely due to its limited CNS penetration.
- the aim of this clinical trial was to evaluate the analgesic efficacy and safety of intravenous (IV) CR845 dosed preoperatively and postoperatively in female patients undergoing an elective laparoscopic hysterectomy. Secondary objectives were: 1. To evaluate the efficacy of CR845 compared to placebo in reducing pain following laparoscopic hysterectomy: (a) to determine the time specific visual analog pain score (VAS) difference, summed pain intensity differences over all time periods (SPIDs) and pain relief, etc. and (b) to evaluate the proportion of patents that were randomized to receive preoperative CR845 and received no rescue medication postoperatively, compared to those who received placebo preoperatively and did not receive any rescue medication; and 2. To evaluate the safety and tolerability of CR845.
- VAS time specific visual analog pain score
- SPIDs summed pain intensity differences over all time periods
- This Phase 2, double-randomized, double-blind, placebo-controlled, parallel group study was conducted in approximately 200 female subjects, aged 18 to 65, across 22 US clinical sites. All subjects were administered a 15-minute IV infusion of 0.04 mg/kg CR845 or matching placebo before surgery in a 1: 1 ratio. After surgery and upon reaching a pain intensity baseline level of at least 4 on a 10 cm visual analog scale (VAS), subjects were also re- randomized in a 1: 1 ratio to receive a second IV infusion of either 0.04 mg/kg of CR845 or placebo.
- VAS 10 cm visual analog scale
- All doubly-randomized patients were thereby randomized to receive one of four possible treatment regimens: placebo-placebo, placebo-CR845, CR845-placebo, or CR845- CR845 (See Fig. 1). Pain intensity and pain relief scores were assessed up to 24 hours following the post-surgery infusion. Patients were allowed IV morphine for rescue at any point during the post-operative period, if requested.
- the main efficacy endpoints were the total morphine consumption in the first 24 hours in patients who were re -randomized in the postoperative period and the efficacy of CR845 in reducing pain intensity including time specific VAS difference; summed pain intensity differences (SPIDs); area under the curve (AUC); pain relief; and the proportion of patients that were randomized to receive preoperative CR845 with no rescue medication postoperatively.
- the safety endpoints included the incidence of adverse events, physical examination, vital signs, 12- lead ECG, clinical laboratory evaluations, and cumulative fluid balance.
- EXAMPLE 2 Relative Levels of Reduction of Post- Operative Pain (SPIDs)
- Fig. 2 shows the relative levels of reduction of post-operative pain over the first
- EXAMPLE 2 Relative Levels of Reduction of Post- Operative Pain (PIDs)
- Fig. 3 shows the relative levels of reduction of post-operative pain over the first
- Fig 4 shows the amounts of morphine (in milligrams) self administered by the patients in each group: placebo-placebo, placebo-CR845, CR845-placebo, and CR845-CR845 in the interval 2-4 hours, 4-12 hours and 12-24 hours post surgery.
- mITT intrathecally delivered morphine
- those patients receiving two doses of CR845 self-administered the least morphine in each time period.
- EXAMPLE 4 Evaluations of Pain Relief Assessed by Patients
- Fig. 5 shows the evaluations of pain relief as assessed by the patients themselves.
- the four patient groups are those receiving pre- and post-operatively respectively:
- the Placebo-Placebo group i.e receiving inactive placebo instead of the peripherally-restricted kappa opioid receptor agonist
- the lowest pain intensity difference i.e. the least pain relief
- the group receiving CR845 before and after surgery showed the highest pain intensity difference (i.e. most pain relief) as judged by PID score.
- EXAMPLE 4 Global Evaluations of Pain Relief Assessed by Patients
- Fig. 6 shows the overall evaluations of pain relief as assessed by the patients themselves.
- the six patient groups are those receiving pre- and post-operatively respectively:
- EXAMPLE 5 Assay of IL6 in patient blood samples
- Cytokine Assays to measure IL6 in 96-well MULTI-ARRAY ® or MULTISPOT ® plates (Meso Scale Discovery, Gaithersburg, MD) according to the manufacturer's instructions.
- the assays employ a sandwich immunoassay format where capture antibodies are coated in a single spot, or in a patterned array, on the bottom of the wells of a MULTIARRAY ® or MULTI-SPOT ® plate.
- IL6 antibody labeled with an electrochemiluminescent compound MSD SULFO-TAGTM label- are added over the course of one or more incubation periods.
- the IL6 in the sample binds to capture antibody immobilized on the working electrode surface; recruitment of the labeled detection antibody by bound cytokine completes the sandwich.
- the user adds an MSD read buffer that provides the appropriate chemical environment for electrochemiluminescence and loads the plate into an MSD SECTOR ® instrument for analysis. Inside the SECTOR ® instrument, a voltage applied to the plate electrodes causes the labels bound to the electrode surface to emit light. The instrument measures intensity of emitted light to provide a quantitative measure of IL6 present in the sample.
- Calibrators are run in duplicate to generate a standard curve.
- the standard curve is modeled using least squares fitting algorithms so that signals from samples with known levels of IL6 can be used to calculate the concentration of analyte in the sample.
- the assays have a wide dynamic range (3-4 logs) which allows accurate quantitation in many samples without the need for dilution.
- the MSD DISCOVERY WORKBENCH® analysis software utilizes a 4- parameter logistic model (or sigmoidal dose-response) and includes a 1/Y2 weighting function. The weighting function is important because it provides a better fit of data over a wide dynamic range, particularly at the low end of the standard curve.
- EXAMPLE 6 Assay of C-reactive protein in patient blood samples
- the Invitrogen Hu CRP kit is a solid phase sandwich Enzyme Linked-Immuno-
- Sorbent Assay useful for the determination of CRP levels in a sample and was used according to the manufacturer's instructions. .
- CRP levels were determined using the C-Reactive Protein High Sensitivity Test by Roche Diagnostics according to the manufacturer's instructions.
- a highly purified antibody is coated onto the wells of the microtiter strips provided.
- standards of known Hu CRP content, controls, and unknown samples were pipetted into the coated wells.
- biotinylated second antibody was added.
- Streptavidin-Peroxidase (enzyme) was added. This binds to the biotinylated antibody to complete the four-member sandwich.
- a substrate solution was added, which was acted upon by the bound enzyme to produce color. The intensity of this colored product is directly proportional to the concentration of Hu CRP present in the original specimen. Results are shown in Fig. 6. Levels of CRP appeared to be comparable between patients treated with CR845 pre- and post-surgically versus placebo. However, it should be noted that CRP is produced by the liver not by immune cells and so may not be a good marker for surgically induced inflammation.
- EXAMPLE 7 Thirteen-Plex assay of cytokines in patient serum samples
- the Human Cytokine MILLIPLEX MAP assay panel with the Luminex® xMAP® microsphere technology optimized format was used to measure serum concentrations of a panel of 13 cytokines: IL- ⁇ , IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13, GM-CSF, IFNy, and TNFa were quantified in human serum samples according to the manufacturer's instructions. Samples were serum samples taken at 1 hour, 8 hours and 24 hours post laparoscopic surgery in a Phase lib clinical trial in which subjects were administered CR845 or placebo as shown in figures 6-14.
- the method uses Luminex® proprietary techniques to internally color-code microspheres with two fluorescent dyes. Assays depend on a hundred distinctly colored microsphere sets, each of which is coated with a specific capture antibody. The cytokine in the test sample is captured by the microspheres, and a biotinylated detection antibody is used as detection agent.- The reaction mixture is then incubated with Streptavidin-PE conjugate, the reporter molecule, to complete the reaction on the surface of each microsphere. The microspheres are then passed rapidly through a laser which excites the internal dyes marking the microsphere set. A second laser excites PE, the fluorescent dye on the reporter molecule. A high-speed digital-signal processor is used to identify each individual microsphere and quantify the result of its bioassay based on fluorescent reporter signals. Multiple results were thus obtained from each sample.
- EXAMPLE 8 Adverse events in subjects treated with CR845 or placebo
- Adverse events (nausea, vomiting and pruritus) occurring in the first 24 hours post laparoscopic surgery are shown in Fig. 15.
- Data are from a Phase lib clinical trial in which subjects were administered CR845 or placebo.
- Generalized pruritus was distinguished from local pruritus events and shown separately in Fig. 15.
- Adverse events were lower in all CR845 treated patient groups as compared with placebo treated patients.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
A method of treating of a mammalian subject suffering from an inflammatory disease or condition by administering a peripherally-restricted kappa opioid receptor agonist for reducing the inflammation is provided. The peripherally-restricted kappa opioid receptor agonist can include a peptide and the peptide can include D-amino acids. Administration of peripherally- restricted kappa opioid receptor agonists results in lowering of serum levels of pro-inflammatory cytokines and elevation of levels of anti-inflammatory cytokines.
Description
PERIPHERAL KAPPA RECEPTOR AGONISTS FOR REDUCING PAIN AND
INFLAMMATION
RELATED APPLICATION
[0001] The present application claims the benefit of U.S. provisional patent application
Serial No. 61/655,731 filed June 5, 2012, the disclosure of which is incorporated by reference herein in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to the prevention, inhibition or treatment of inflammation, especially inflammation resulting from surgical procedures or other bodily insult. More particularly, the invention relates to the administration of peripherally-restricted kappa opioid receptor agonists to reduce post-surgical inflammation.
RELATED ART
[0003] Non-narcotic analgesics, such as the non-steroidal anti-inflammatory drugs
(NSAIDs) have been used for the management and treatment of pain and inflammation. However, the NSAIDs (e.g. ibuprofen) also have unwanted side effects such as hepatotoxicity and ulcers and gastric bleeding due to Coxl activity. There is a need for analgesics and antiinflammatory agents that are free of these side effects of NSAIDs.
[0004] Morphine acts at the mu opioid receptor to produce its analgesic effects.
Compounds acting at the kappa opioid receptor can relieve pain and also suppress inflammation. US patent 5,965,701 to Junien et al. discloses kappa receptor agonists which have an affinity for the KOR at least 1,000 times their affinity for the mu opioid receptor and an ED50 of not greater than about 0.5 mg/kg. US patents 7,402,564; 7,727,963 and 7,713,937 disclose synthetic peptide amides that are kappa opioid receptor ligands and exhibit low P450 CYP inhibition and low penetration into the brain. US patent 7,842,662 discloses dimeric forms of the synthetic peptide amides that retain their kappa receptor agonist properties.
[0005] US patent application no.12/768,686 discloses the administration of the kappa opioid agonist synthetic peptide amides by intravenous, oral and topical routes. US patent application publication no. 2010/0075910 discloses the use of the kappa opioid agonist synthetic peptide amides for the treatment of inflammatory pain.
[0006] The morphine- sparing effects of one such the kappa opioid agonist synthetic peptide amide, CR845, administered to women after laparoscopic-assisted hysterectomy has been reported (Menzaghi et al., 2010 13th World Congress on Pain). In this reported Phase 2 clinical trial, subjects were administered a 15-minute intravenous infusion of 0.04 mg/kg CR845 or matching placebo following recovery from surgery and reaching a pain intensity baseline level of from 5 to 8 on a scale of zero to 11. Pain intensity was assessed up to 8 hours after the CR845 infusion or until morphine was administered by patient controlled analgesia. Morphine use was reduced by 32% over the first 16 hours post- infusion in CR845-treated patients versus placebo accompanied by a significant reduction in opioid side effects (vomiting, nausea and pruritis, i.e. itching) with no significant changes in clinical lab test results, vital signs, electrocardiograms, or Ramsey sedation scale assessment. CR845 was shown to be safe and well tolerated, and effective in reducing pain intensity when administered after surgery.
[0007] The link between cytokines and inflammation is well documented. See for instance: "Cytokines in Disease" Whicher, J.T. and S.W. Evans (1990) Clin. Chem. 36(7) 1269- 1281; "Cytokines and Inflammation" Ed. E. S. Kimball, (1991) CRC Press, Inc., 2000 Boca Raton, FL; and "Cytokines and Inflammation" Aarons, A. and L. Borish, (1993) Immuno Methods 3(1) 3-12; and "Role of pro-and anti-inflammatory cytokines during inflammation: experimental and clinical findings " C. A. Dinarello J. Biological Regulators and Homeostatic Agents. (1997) 11: (3) 91-103.
BRIEF DESCRIPTIONS OF THE FIGURES
[0008] Fig. 1 shows the design of the clinical trial described in Example 1. N: Number of patients; VAS: visual analog pain scale; PACU: post anesthesia care unit; Opioid Rescue prn: Pro re nata - Opioid rescue "as needed."
[0009] Fig. 2 shows the relative levels of reduction of post-operative pain over the first
24 hours after surgery as demonstrated by the summed pain intensity difference (SPID) over all time points. Columns are mean values, and the bars are standard errors about the mean (SEM).
[0010] Fig. 3 shows the relative levels of reduction of post-operative pain over the first
24 hours after surgery as demonstrated by the pain intensity difference (PID) from zero to 24 hours.
[0011] Fig 4 shows the amounts of morphine (in milligrams) self administered by the patients in each group: placebo-placebo, placebo-CR845, CR845-placebo, and CR845-CR845 in the intervals: 2-4 hours, 4-12 hours and 12-24 hours post surgery.
[0012] Fig. 5 shows the evaluations of pain relief as assessed by the patients themselves, demonstrating that pre-treatment with CR845 was consistently evaluated as very good or excellent by the highest percentage of patients.
[0013] Fig. 6 shows the results of C-reactive protein assays in samples of patient serum taken pre surgery and at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
[0014] Fig. 7 shows the results of IL-6 assays in samples of patient serum taken pre surgery and at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
[0015] Fig. 8A shows the results of TNFa assays and Fig. 8B shows the results of IL-Ιβ assays in samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
[0016] Fig. 9A shows the results of IL-2 assays and Fig. 9B shows the results of IL-8 assays in samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845. The difference in the change from baseline level of IL-8 was highly significant (p=0.007).
[0017] Fig. 10A shows the results of IL-12 assays and Fig. 10B shows the results of
GM-CSF assays in samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
[0018] Fig. 11A shows the results of IL-6 assays and Fig. 11B shows the results of IL-7 assays in samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
[0019] Fig. 12A shows the results of IL-4 assays and Fig. 12B shows the results of IFNy assays from samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving placebo or a single dose of CR845.
[0020] Fig. 13A shows the results of IL-5 assays and Fig. 13B shows the results of IL-10 assays in samples of patient serum taken at 1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving two placebos or two doses of CR845.
[0021] Fig. 14 shows the results of IL-13 assays from samples of patient serum taken at
1 hour, 8 hours and 24 hours post laparoscopic hysterectomy after receiving placebo or a single dose of CR845.
[0022] Fig. 15 shows the incidence of treatment emergent adverse events (TEAEs) including nausea, vomiting, pruritus and generalized pruritus through 24 hours after first infusion of CR845 after laparoscopic hysterectomy in a Phase lib trial.
SUMMARY
[0023] In one embodiment the present invention provides a method for reducing kappa opioid receptor-associated inflammation in a mammalian subject, wherein the method includes administering an effective amount of a peripherally-restricted kappa opioid receptor agonist to the subject. In one embodiment the inflammation is due to an inflammatory disease or condition. In another embodiment the inflammation is due to a medical procedure.
[0024] In another embodiment the present invention provides a method for reducing kappa opioid receptor-associated inflammation in a mammalian subject, the method includes administering an effective amount of a peripherally-restricted kappa opioid receptor agonist and wherein the administering of the peripherally restricted kappa opioid receptor agonist causes a reduction in the level of one or more pro-inflammatory cytokines and/or the increase in an level of one or more anti-inflammatory cytokines in the blood of the subject. In one embodiment the pro-inflammatory cytokines are chosen from IL-Ιβ, IL-2, IL-4 IL-6, IL-7, IL-8, IL-12(p70), GM-CSF, TNFa and IFNy. In another embodiment the anti-inflammatory cytokines are chosen from IL-5, IL-10 and IL-13.
[0025] The invention provides the first-in-man use of a non-narcotic kappa opioid receptor agonist analgesic used as a pretreatment prior to and/or during surgery to reduce pain and inflammation. The peripheral restriction of the kappa opioid receptor agonist analgesics of the invention provides the non-narcotic analgesic and anti-inflammatory properties due to action at peripheral kappa receptors and very limited penetration across the blood brain barrier, and therefore little or no action at the kappa receptors in the CNS and the brain.
[0026] In another embodiment, the present invention provides a method for reducing kappa opioid receptor- associated inflammation in a mammalian subject, the method comprising
administering an effective amount of a peripherally restricted kappa opioid receptor agonist to the subject and thereby reducing the kappa opioid receptor-associated inflammation in the mammalian subject.
[0027] The kappa opioid receptor-associated inflammation can be any inflammatory disease or condition including, but not limited to sinusitis, rheumatoid arthritis tenosynovitis, bursitis, tendonitis, lateral epicondylitis, adhesive capsulitis, osteomyelitis, osteoarthritic inflammation, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ocular inflammation, otitic inflammation or autoimmune inflammation.
[0028] In one embodiment, the present invention provides a method for reducing post medical procedure inflammation in a mammalian subject, the method comprising administering an effective amount of a peripherally restricted kappa opioid receptor agonist to the subject prior to the medical procedure that normally causes post- medical procedure inflammation and thereby reducing the post-medical procedure inflammation experienced by the subject.
[0029] The subject can be a human patient, a non-human primate or any other mammal.
The non-human primate can be any non-human primate such as, for instance an ape, gorilla, orangutan, lemur, monkey or chimpanzee. The non-primate mammal can be the non-primate mammal such as a pet or companion animal, e.g. a dog or a cat; a high-value mammal such as a thoroughbred horse, a show animal or a farm animal, such as a cow, a goat, a sheep or a pig.
[0030] In another embodiment, the invention provides a method for reducing patient need for morphine, such as for instance as judged by patient controlled analgesia (PCA) demand.
[0031] In another embodiment, the peripherally restricted kappa opioid receptor agonist useful in the practice of the present invention includes a peptide. The peptide can include any amino acid, such as for instance a natural amino acid, an L-amino acid, a D-amino acid, or a non- natural amino acid, such as for instance, and without limitation, D-Ala(cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), D-Ala(thienyl), D-Nle (i.e., D-norleucine) or (a-Me)D-Leu.
[0032] In another embodiment, the peptide includes at least four D-amino acids. In still another embodiment, the peripherally restricted kappa opioid receptor agonist includes a synthetic peptide amide having the formula I:
Rr(V)e-R2 Formula I
or a stereoisomer, mixture of stereoisomers, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, N-oxide or isomorphic crystalline form thereof.
[0033] In one embodiment, the residue Xaai can be any of the following: (A)(A')D-Phe,
(A)(A')(a-Me)D-Phe, D-Tyr, D-Tic, D-tert-leucine, D-neopentylglycine, D-phenylglycine, D-homophenylalanine, and P-(E)D-Ala, and wherein each (A) and each (Α') are phenyl ring substituents independently selected from the group consisting of -H, -F, -CI, -N02, -CH3, -CF3, - CN, and -CONH2, and wherein each (E) is independently selected from the group consisting of cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, thienyl and thiazolyl.
[0034] In another embodiment, the residue Xaa2 is selected from the group consisting of
(A) (A')D-Phe, 3,4-dichloro-D-Phe, (A)(A')(a-Me)D-Phe, D-lNal, D-2Nal, D-Tyr, (E)D-Ala and D-Trp.
[0035] In another embodiment, the residue Xaa3 is selected from the group consisting of
D-Nle, D-Phe, (E)D-Ala, D-Leu, (a-Me)D-Leu, D-Hle, D-Val, and D-Met.
[0036] In another embodiment, the residue Xaa4 is selected from the group consisting of
(B) 2D-Arg, (B)2D-Nar, (B)2D-Har, ζ-(Β)ϋ-Η1 8, D-Dap, s-(B)D-Lys, s-(B)2-D-Lys, D-Amf, amidino-D-Amf, y-(B)2D-Dbu, 5-(B)2a-(B')D-Orn, D-2-amino-3(4-piperidyl)propionic acid, D- 2-amino-3(2-aminopyrrolidyl)propionic acid, D-a-amino-P-amidinopropionic acid, a-amino-4- piperidine- acetic acid, cis-a,4-diaminocyclohexane acetic acid, trans-a,4-diaminocyclohexane- acetic acid, cis-a-amino-4-methylaminocyclo-hexane acetic acid, trans-a-amino-4-methylamino- cyclohexane acetic acid, a-amino-l-amidino-4-piperidineacetic acid, cis-a-amino-4-guanidino- cyclohexane acetic acid, and trans-a-amino-4-guanidinocyclohexane acetic acid, wherein each (B) is independently selected from -H and CrC4 alkyl, and (Β') is H or (a-Me).
[0037] In another embodiment, the linking group, W is selected from the group consisting of: Null, provided that when W is null, Y is N; -NH-(CH2)b- with b equal to zero, 1, 2, 3, 4, 5, or 6; and -NH-(CH2)c-0- with c equal to 2, or 3, provided that Y is C.
[0038] In another embodiment the moiety
is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein all ring heteroatoms in said ring moiety are N; wherein Y and Z are each independently C or N.
[0039] In another embodiment the moiety
is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein all ring heteroatoms in said ring moiety are N; wherein Y and Z are each independently C or N, provided that when such ring moiety is a six, seven or eight-membered ring, Y and Z are separated by at least two ring atoms.
[0040] In another embodiment the moiety
is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein all ring heteroatoms in said ring moiety are N; wherein Y and Z are each independently C or N provided that when such ring moiety has a single ring heteroatom which is N, then such ring moiety is non-aromatic; the group, V is C -C alkyl, and e is zero or 1, wherein when e is zero, then V is null and and R2 are directly bonded to the same or different ring atoms.
[0041] In another embodiment (i) R is selected from the group consisting of -H, -OH, halo, -CF3, -NH2, -COOH, C C6 alkyl, CrC6 alkoxy, amidino, CrC6 alkyl-substituted amidino, aryl, optionally substituted heterocyclyl, Pro-amide, Pro, Gly, Ala, Val, Leu, He, Lys, Arg, Orn, Ser, Thr, -CN, -CONH2, -COR', -S02R', -CONR'R", -NHCOR', OR' and S02NR'R"; wherein said optionally substituted heterocyclyl is optionally singly or doubly substituted with
substituents independently selected from the group consisting of CrC6 alkyl, CrC6 alkoxy, oxo, -OH, -CI, -F, -NH2, -N02, -CN, -COOH, and amidino; wherein R' and R" are each independently -H, Ci-Cg alkyl, aryl, or heterocyclyl or R' and R" are combined to form a 4- to 8-membered ring, which ring is optionally singly or doubly substituted with substituents independently selected from the group consisting of Ci-C6 alkyl, -Ci-C6 alkoxy, -OH, -CI, -F, -NH2, -N02, -CN, -COOH and amidino; and R2 is selected from the group consisting of -H, amidino, singly or doubly CrC6 alkyl-substituted amidino, -CN, -CONH2, -CONR'R", -NHCOR', -S02NR'R" and -COOH; or
(ii) Ri and R2 taken together can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety which is bonded to a single ring atom of the Y and Z-containing ring moiety;
(iii) Ri and R2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4- to 8-membered heterocyclic ring moiety to form a spiro structure; or
(iv) Ri and R2 taken together with two or more adjacent ring atoms of the Y and Z- containing ring moiety can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety; wherein each of said optionally substituted 4-, 5-, 6,-, 7-, 8- and 9-membered heterocyclic ring moieties comprising Ri and R2 is optionally singly or doubly substituted with substituents independently selected from the group consisting of C -C alkyl, C -C alkoxy, optionally substituted phenyl, oxo, -OH, -CI, -F, -NH2, -N02, -CN, -COOH, and amidino.
[0042] In one embodiment of the invention, the post-medical procedure inflammation is due to a medical procedure selected from the following procedures: appendectomy, open colorectal surgery, hernia repair, prostatectomy, colonic resection, gastrectomy, splenectomy, colectomy, colostomy, pelvic laparoscopy, tubal ligation, hysterectomy, vasectomy, cholecystectomy, colonoscopy, cystoscopy, hysteroscopy, cervical and endometrial biopsy. Other relevant medical procedures include ocular surgery procedures, such as for instance, canaloplasty, laser eye surgery and refractive surgery, such as lasik surgery (laser-assisted in-situ keratomileusis) and other corneal surgery including corneal replacement surgery, cataract surgery and retinal surgery. The term "post-medical procedure" pain and inflammation is used interchangeably with the term "post-surgical" pain and inflammation in this specification.
[0043] In still other embodiments the post-medical procedure inflammation may be due to an orthopedic procedure, such as for instance knee or shoulder arthroscopy, knee joint and hip joint replacement, carpel tunnel release, anterior cruciate ligament reconstruction, repair of femoral neck or ankle fracture, meniscectomy and laminectomy, to name but a few. Other orthopedic procedures addressable by the present invention will be immediately apparent to clinicians, surgeons and those of skill in the art.
DETAILED DESCRIPTION
[0044] The D-isomer of an amino acid is specified by the prefix "D-" as in "D-Phe" which represents D-phenylalanine, the D-isomer of phenylalanine. Similarly, the L-isomer is specified by the prefix "L-" as in "L-Phe." As used herein, D-Arg represents D-arginine, D-Har represents D-homoarginine, which has a side chain one methylene group longer than D-Arg, and D-Nar represents D-norarginine, which has a side chain one methylene group shorter than D- Arg. Similarly, D-Leu means D-leucine, D-Nle means D-norleucine, and D-Hle represents D- homoleucine. D-Ala means D-alanine, D-Tyr means D-tyrosine, D-Trp means D-tryptophan, and D-Tic means D-l,2,3,4-tetrahydroisoquinoline-3carboxylic acid. D-Val means D-valine and D-Met means D-methionine. D-Pro means D-proline, Pro-amide means the D- or L- form of proline amide. D-Pro amide represents D-proline with an amide formed at its carboxy moiety wherein the amide nitrogen may be alkyl substituted, as in -NRaRb, wherein Ra and Rb are each independently a Ci-C6 alkyl group, or one of Ra and R is -H. Gly means glycine, D-Ile means D-isoleucine, D-Ser means D-serine, and D-Thr means D-threonine. (E)D-Ala means the D- isomer of alanine which is substituted by the substituent (E) on the β-carbon. Examples of such substituent (E) groups include tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, furyl, pyridyl, thienyl, thiazolyl and benzothienyl. Thus, cyclopentyl-D-Ala means the D-isomer of alanine which is substituted by cyclopentyl on the β-carbon. Similarly, D-Ala(2-thienyl) and (2- thienyl)D-Ala are interchangeable and both mean the D-isomer of alanine substituted at the β- carbon with thienyl that is attached at the 2- ring position.
[0045] As used herein, D-Nal means the D-isomer of alanine substituted by naphthyl on the β-carbon. D-2Nal means naphthyl substituted D-alanine wherein the attachment to naphthalene is at the 2-position on the ring structure and D-lNal means naphthyl- substituted D- alanine wherein the attachment to naphthalene is at the 1-position on the ring structure. By (A)( A')D-Phe is meant D-phenylalanine substituted on the phenyl ring with one or two substituents
independently chosen from halo, nitro, methyl, halomethyl (such as, for example, trifluoromethyl), perhalomethyl, cyano and carboxamide. By D-(4-F)Phe is meant D- phenylalanine which is fluoro-substituted in the 4-position of the phenyl ring. By D-(2-F)Phe is meant D-phenylalanine which is fluoro-substituted in the 2-position of the phenyl ring. By D-(4- Cl)Phe is meant D-phenylalanine which is chloro substituted in the 4- phenyl ring position. By (a-Me)D-Phe is meant D-phenylalanine which is methyl substituted at the alpha carbon. By (a-Me)D-Leu is meant D-leucine which is methyl substituted at the alpha carbon.
[0046] The designations (B)2D-Arg, (B)2D-Nar, and (B)2D-Har represent D-arginine, D- norarginine and D-homoarginine, respectively, each having two substituent (B) groups on the side chain. D-Lys means D-lysine and D-Hlys means D-homolysine.
s-(B)D- Lys, and s-(B)2-D-Lys represent D-homolysine and D-lysine each having the side chain amino group substituted with one or two substituent (B) groups, as indicated. D-Orn means D-ornithine and 5-(B)a-(B')D-Orn means D-ornithine substituted with (Β') at the alpha carbon and substituted with (B) at the side chain δ-amino group.
[0047] D-Dap means D-2,3-diaminopropionic acid. D-Dbu represents the D-isomer of alpha, gamma-diamino butyric acid and (B)2D-Dbu represents alpha, gamma-diamino butyric acid which is substituted with two substituent (B) groups at the gamma amino group. Unless otherwise stated, each of the (B) groups of such doubly substituted residues are independently chosen from H- and C1-C4-alkyl. As used herein, D-Amf means D-(NH2CH2-)Phe, i.e., the D- isomer of phenylalanine substituted with aminomethyl on its phenyl ring and D-4Amf represents the particular D-Amf in which the aminomethyl is attached at the 4- position of the ring. D-Gmf means D-Amf(amidino) which represents D-Phe wherein the phenyl ring is substituted with -CH2NHC(NH)NH2. Amd represents amidino, -C(NH)NH2, and the designations (Amd)D-Amf and D-Amf(Amd) are also interchangeably used for D-Gmf. The designations Ily and lor are respectively used to mean isopropyl Lys and isopropyl Orn, wherein the side chain amino group is alkylated with an isopropyl group.
[0048] Alkyl means an alkane radical which can be a straight, branched, and cyclic alkyl group such as, but not limited to, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, t-butyl, sec-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, cyclohexylethyl. i to alkyl refers to alkyl groups having between one and eight carbon atoms. Similarly, CrC6 alkyl refers to alkyl groups having between one and six carbon atoms. Likewise, C C4 alkyl refers to alkyl groups having
between one and four carbon atoms. By lower alkyl is meant C C6 alkyl. Me, Et, Pr, Ipr, Bu, and Pn are interchangeably used to represent the common alkyl groups: methyl, ethyl, propyl, isopropyl, butyl, and pentyl, respectively. Although the linkage for an alkyl group is typically at one end of an alkyl chain, the linkage may be elsewhere in the chain, e.g. 3-pentyl which may also be referred to as ethylpropyl, or 1-ethylprop- l-yl. Alkyl-substituted, such as i to C6 alkyl- substituted amidino, indicates that the relevant moiety is substituted with one or more alkyl groups.
[0049] Where a specified moiety is null, the moiety is absent and if such moiety is indicated to be attached to two other moieties, such two other moieties are connected by one covalent bond. Where a connecting moiety is shown herein as attached to a ring at any position on the ring, and attached to two other moieties, such as R and R2, in the case where the connecting moiety is specified to be null, then the ¾ and R2 moieties can each be independently attached to any position on the ring.
[0050] The terms "heterocycle", "heterocyclic ring" and "heterocyclyl" are used interchangeably herein and refer to a ring or ring moiety having at least one non-carbon ring atom, also called a heteroatom, which can be a nitrogen atom, a sulfur atom, or an oxygen atom. Where a ring is specified as having a certain number of members, the number defines the number of ring atoms without reference to any substituents or hydrogen atoms bonded to the ring atoms. Heterocycles, heterocyclic rings and heterocyclyl moieties can include multiple heteroatoms independently selected from nitrogen, sulfur, or oxygen atom in the ring. Rings can be substituted at any available position. For example, but without limitation, 6- and 7-membered rings are often substituted in the 4- ring position and 5-membered rings are commonly substituted in the 3- position, wherein the ring is attached to the peptide amide chain at the 1-ring position.
[0051] The term "saturated" means an absence of double or triple bonds and the use of the term in connection with rings describes rings having no double or triple bonds within the ring, but does not preclude double or triple bonds from being present in substituents attached to the ring.
[0052] The term "non-aromatic" in the context of a particular ring refers to an absence of aromaticity in that ring, but does not preclude the presence of double bonds within the ring, including double bonds which are part of an aromatic ring fused to the ring in question. Nor is a
ring atom of a saturated heterocyclic ring moiety precluded from being double-bonded to a non- ring atom, such as for instance a ring sulfur atom being double-bonded to an oxygen atom substituent. As used herein, heterocycles, heterocyclic rings and heterocyclyl moieties also include saturated, partially unsaturated and hetero aromatic rings and fused bicyclic ring structures unless otherwise specified. A heterocycle, heterocyclic ring or heterocyclyl moiety can be fused to a second ring, which can be a saturated, partially unsaturated, or aromatic ring, which ring can be a heterocycle or a carbocycle.
[0053] Where indicated, two substituents can be optionally taken together to form an additional ring. Rings may be substituted at any available position. A heterocycle, heterocyclic ring and heterocyclyl moiety can, where indicted, be optionally substituted at one or more ring positions with one or more independently selected substituents, such as for instance, C -C alkyl, C3-C8 cycloalkyl, C -C alkoxy, halo Ci-C6 alkyl, optionally substituted phenyl, aryl, heterocyclyl, oxo, -OH, -CI, -F, -NH2, -N02, -CN, -COOH and amidino. Suitable optional substituents of the phenyl substituent include for instance, but without limitation, one or more groups selected from C C3 alkyl, C C3 alkoxy, halo C C3 alkyl, oxo, -OH, -CI, -F, -NH2, -N02, -CN, -COOH and amidino.
[0054] D-Phe and substituted D-Phe are examples of a suitable amino acid for residue
Xaai in Formula I. The phenyl ring can be substituted at any of the 2-, 3- and/or 4-positions. Particular examples of permitted substitutions include, for instance, chlorine or fluorine at the 2- or 4- positions. Also the alpha-carbon atom may be methylated. Other equivalent residues which represent conservative changes to D-Phe can also be used. These include D-Ala(cyclo- pentyl), D-Ala(thienyl), D-Tyr and D-Tic. The residue at the second position, Xaa2 can also be D-Phe or substituted D-Phe with such substitutions including a substituent on the 4-position carbon of the phenyl ring, or on both the 3- and 4-positions. Alternatively, Xaa2 can be D-Trp, D-Tyr or D-alanine substituted by naphthyl. The third position residue, Xaa3 can be any non- polar amino acid residue, such as for instance, D-Nle, D-Leu, (a-Me)D-Leu, D-Hle, D-Met or D- Val. However, D-Ala(cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) or D-Phe can also be used as Xaa3. The fourth position residue Xaa4 can be any positively charged amino acid residue, such as for instance, D-Arg and D-Har, which can be optionally substituted with lower alkyl groups, such as one or two ethyl groups. Alternatively, D-Nar and any other equivalent residues can be used, such as, for instance, D-Lys or D-Orn (either of which can be co-amino
group alkylated, for example by methyl or isopropyl groups, or methylated at the cc-carbon group). Moreover, D-Dbu, D-4-Amf (which can be optionally substituted with amidino), and D- Hlys are also suitable amino acids at this position.
[0055] Compounds of the invention contain one or more chiral centers, each of which has two possible three-dimensional spatial arrangements (configurations) of the four substituents around the central carbon atom. These are known as "stereoisomers", and more specifically as "enantiomers" (all chiral centers inverted) or "diastereoisomers" (two or more chiral centers, at least one chiral center remaining the same). In a specific embodiment of the invention, the amino acids which make up the tetrapeptide backbone, XaaiXaa2Xaa3Xaa4 are specified to be D- amino acids i.e., the opposite configuration to those generally found in mammals.
[0056] References to stereoisomers of the synthetic peptide amides of the invention in this specification relate to chiral centers other than the alpha carbons of the D-amino acids which make up Xaai-Xaa4. Thus, stereoisomers of synthetic peptide amides that are embodiments of the invention wherein each of XaarXaa4 are specified to be D-amino acids, do not include L- amino acids or racemic mixtures of the amino acids at these positions. Similarly, reference to racemates herein concerns a center other than the alpha carbons of the D-amino acids which make up Xaai-Xaa4. Chiral centers in the synthetic peptide amides of the invention for which a stereoisomer may take either the R or S configuration include chiral centers in the moiety attached to the carboxy-terminus of Xaa4, and also chiral centers in any amino acid side chain substituents of Xaai-Xaa4.
[0057] As used herein, "effective amount" or "sufficient amount" of the peripherally- restricted kappa receptor agonists of the invention such as the synthetic peptide amides refers to an amount of the compound as described herein that may be therapeutically effective to inhibit, prevent, or treat a symptom of a particular disease, disorder, condition, or side effect. As used herein, a "reduced dose" of a mu opioid agonist analgesic compound refers to a dose which when used in combination with a kappa opioid agonist, such as a synthetic peptide amide of the invention, is lower than would be ordinarily provided to a particular patient, for the purpose of reducing one or more side effects of the compound. The dose reduction can be chosen such that the decrease in the analgesic or other therapeutic effect of the compound is an acceptable compromise in view of the reduced side effect(s), where the decrease in analgesic or other
therapeutic effects of the mu opioid agonist analgesic are wholly or at least partially offset by the analgesic or other therapeutic effect of the synthetic peptide amide of other peripherally- restricted kappa receptor agonist of the invention.
[0058] Co-administration of a mu opioid agonist analgesic compound with a synthetic peptide amide or other peripherally-restricted kappa receptor agonist of the invention also permits incorporation of a reduced dose of the peripherally-restricted kappa receptor agonist or synthetic peptide amide and/or the mu opioid agonist analgesic compound to achieve the same therapeutic effect as a higher dose of the synthetic peptide amide/other peripherally-restricted kappa receptor agonist or the mu opioid agonist analgesic compound if administered alone.
[0059] As used herein, "pharmaceutically acceptable" refers to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without severe toxicity, irritation, allergic response, or other complications, commensurate with a benefit-to-risk ratio that is reasonable for the medical condition being treated.
[0060] As used herein, "dosage unit" refers to a physically discrete unit suited as unitary dosages for a particular individual or condition to be treated. Each unit may contain a predetermined quantity of active synthetic peptide amide or other peripherally-restricted kappa receptor agonist compound(s) calculated to produce the desired therapeutic effect(s), optionally in association with a pharmaceutical carrier. The specification for the dosage unit forms may be dictated by (a) the unique characteristics of the active compound or compounds, and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such active compound or compounds. The dosage unit is often expressed as weight of compound per unit body weight, for instance, in milligrams of compound per kilogram of body weight of the subject or patient (mg/kg). Alternatively, the dosage can be expressed as the amount of the compound per unit body weight per unit time, (mg/kg/day) in a particular dosage regimen. In a further alternative, the dosage can be expressed as the amount of compound per unit body surface area (mg/m ) or per unit body surface area per unit time
(mg/m /day). For topical formulations, the dosage can be expressed in a manner that is conventional for that formulation, e.g., a one-half inch ribbon of ointment applied to the eye,
where the concentration of compound in the formulation is expressed as a percentage of the formulation.
[0061] As used herein, a "pharmaceutically acceptable salt" refers to a derivative of a compound wherein the parent compound is modified by making an acid or a base salt thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For instance, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric acids and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic acids, and the like.
[0062] These physiologically acceptable salts are prepared by methods known in the art, e.g., by dissolving the free amine bases with an excess of the acid in aqueous alcohol, or neutralizing a free carboxylic acid with an alkali metal base such as a hydroxide, or with an amine. Thus, a pharmaceutically acceptable salt of a synthetic peptide amide or other peripherally-restricted kappa receptor agonist can be formed from any such peptide amide having either acidic, basic or both functional groups. For example, a peptide amide having a carboxylic acid group, may in the presence of a pharmaceutically suitable base, form a carboxylate anion paired with a cation such as a sodium or potassium cation. Similarly, a peptide amide having an amine functional group may, in the presence of a pharmaceutically suitable acid such as HC1, form a salt.
[0063] An example of a pharmaceutically acceptable solvate of a synthetic peptide amide or other peripherally-restricted kappa receptor agonist is a combination of a synthetic peptide amide or other peripherally-restricted kappa receptor agonist with solvent molecules which yields a complex of such solvent molecules in association with the synthetic peptide amide or other peripherally-restricted kappa receptor agonist. Combinations of a drug and propylene
glycol (1,2-propanediol) have been used to form pharmaceutical drug solvates. See for example U.S. patent No. 3,970,651. Other suitable solvates are hydrates of drug compounds. Such hydrates include hydrates which either have comparable activity or hydrates which are converted back to the active compound following administration. A pharmaceutically acceptable N-oxide of a synthetic peptide amide or other peripherally-restricted kappa receptor agonist is such a compound that contains an amine group wherein the nitrogen of the amine is bonded to an oxygen atom.
[0064] A pharmaceutically acceptable crystalline, isomorphic crystalline or amorphous form of a synthetic peptide amide or other peripherally-restricted kappa receptor agonist of the invention can be any crystalline or non-crystalline form of a pharmaceutically acceptable acidic, basic, zwitterionic, salt, hydrate or any other suitably stable, physiologically compatible form of the synthetic peptide amide or other peripherally-restricted kappa receptor agonist according to the invention.
[0065] The synthetic peptide amides or other peripherally-restricted kappa receptor agonists of the invention can be incorporated into pharmaceutical compositions. The compositions can include an effective amount of the synthetic peptide amide or other peripherally-restricted kappa receptor agonist in a pharmaceutically acceptable diluent, excipient or carrier. Conventional excipients, carriers and/or diluents for use in pharmaceutical compositions are generally inert and make up the bulk of the preparation.
[0066] In one embodiment, the present invention provides a method for reducing post medical procedure pain, post medical procedure inflammation, or both in a mammalian subject, the method comprising administering an effective amount of a peripherally restricted kappa opioid receptor agonist to the subject prior to the medical procedure that normally causes post- medical procedure pain, post-medical procedure inflammation, or both and thereby reducing the post-medical procedure pain and/or the post-medical procedure inflammation experienced by the subject; wherein the peripherally restricted kappa opioid receptor agonist has the structure of formula I:
Ri-(V)e-R2 Formula I
wherein the Y and Z-containing ring moiety is a six or seven membered ring having a single ring heteroatom and e is zero, then R is not -OH, and R and R2 are not both -H.
[0067] In another embodiment when the Y and Z-containing ring moiety of formula I is a six membered ring having two ring heteroatoms, both Y and Z are N and W is null, then
-(V)eRiR2 is attached to a ring atom other than Z; and when e is zero, then R and R2 are not both
-H.
[0068] In another embodiment of the synthetic peptide useful in the practice of the present invention, XaaiXaa2 of formula I is D-Phe-D-Phe, Xaa3 is D-Leu or D-Nle and Xaa4 is selected from the group consisting of (B)2D-Arg, D-Lys, (B)2D-Har,
D-Dap, ε- (B)D-Lys, s-(B)2-D-Lys, D-Amf, amidino-D-Amf, y-(B)2D-Dbu and 5-(B)2a-(B')D-Orn.
[0069] In another embodiment of the synthetic peptide of formula I useful in the practice of the present invention, Xaa4 is selected from D-Lys, (B)2D-Har, s-(B)D-Lys and s-(B)2-D-Lys.
[0070] In still another embodiment of the synthetic peptide of formula I useful in the practice of the present invention, W is null, Y is N and Z is C.
[0071] In another embodiment of the synthetic peptide of formula I, the Y and Z- containing ring moiety is a six-membered saturated ring comprising a single ring heteroatom.
[0072] In another embodiment of the synthetic peptide of formula I useful in the practice of the present invention, the groups R and R2 taken together with zero, one or two ring atoms of the Y and Z-containing ring moiety comprise a monocyclic or bicyclic 4-9 membered heterocyclic ring moiety.
[0073] In still another embodiment of the synthetic peptide of formula I useful in the practice of the present invention, the moiety e is zero and the groups R and R2 are each bonded directly to the same ring atom, Rx is H, OH, -NH2, -COOH, -CH2COOH, C C3 alkyl, amidino, C C3 alkyl-substituted amidino, dihydroimidazole, D-Pro, D-Pro amide, or CONH2 and R2 is H, -COOH, or CrC3 alkyl.
[0074] In another embodiment of the synthetic peptide of formula I useful in the practice of the present invention, the moiety:
[0075] In another embodiment of the synthetic peptide of formula I useful in the practice of the present invention, Xaa^aa2 is D-Phe-D-Phe, Xaa3 is D-Leu or D-Nle and Xaa4 is selected from (B)2D-Arg, D-Lys, (B)2D-Har, ζ-(Β)ϋ-Η^, D-Dap, s-(B)D-Lys, s-(B)2-D-Lys, D-Amf, amidino-D-Amf, y-(B)2D-Dbu and 5-(B)2a-(B')D-Orn.
[0076] In another embodiment of the synthetic peptide useful in the practice of the present invention is CR845 having the structure: D-Phe-D-Phe-D-Leu-D-Lys-[co(4- aminopiperidine-4-carboxylic acid -OH:
[0077] Asimadoline, a selective, non-peptidic kappa-opioid receptor agonists is also useful I methods according to the present invention for pretreatment prior to surgery in order to reduce post-surgical pain and inflammation. Asimadoline has the diarylacetamide structure shown below:
(N-[(lS)-2-[(3S)-3-hydroxypyrrolidin-l-yl]-l-phenylethyl]-N-methyl-2,2-diphenylacetamide).
[0078] Nalfurafine (also known as AC-820, TRK-820) is a kappa opioid receptor agonist marketed as a treatment for uremic pruritus in hemodialysis patients. Nalfurafine is another kappa opioid receptor agonist useful according to the present invention for pretreatment prior to surgery in order to reduce post-surgical pain and inflammation.
[0079] Nalfurafine is (2E)-N-[(5a,6P)-17-(cyclopropylmethyl)- 3,14-dihydroxy- 4,5- epoxymorphinan- 6-yl]- 3-(3-furyl)- N-methylacrylamide, and has the following chemical structure:
[0080] In one embodiment of the invention, the method further includes administering another dose of the peripherally restricted kappa opioid receptor agonist to the subject during or after the medical procedure.
[0081] In another embodiment of the method of the invention, the relief from post- medical procedure pain is such that the subject self administers little or no patient controlled analgesia (PCA) after surgery and/or during recovery.
[0082] In another embodiment of the method of the invention, the relief from post- medical procedure inflammation is accompanied by relief from pruritis during the period of recovery from the medical procedure.
[0083] In one embodiment of the invention, the peripherally restricted kappa opioid receptor agonist useful in the practice of the present invention is a non-narcotic analgesic.
[0084] In another embodiment of the method of the invention, the peripherally restricted kappa opioid receptor agonist is administered by a route of injection selected from the group consisting of subcutaneous injection, intravenous injection, intraperitoneal injection, intraarticular injection, intramuscular injection or intra-ocular injection.
[0085] Inflammation is a complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. Inflammation can be acute or chronic, and is often characterized by fever in mammals. Inflammation is a protective response to an inflammatory stimulus and initiates wound-healing processes. Interleukin-6 (IL6) is an antiinflammatory cytokine. The level of C-reactive protein (CRP) in blood rise in the acute phase of inflammation. Therefore, the level of CRP is a useful indicator of an acute inflammatory
response. The level of C-reactive protein can be determined by commercially available ELISA assays. IL6 and CRP have been as clinical markers of inflammation, see for instance Esme et al. (2011) Effects of Flurbiprofen on CRP, TNF- , IL6 and Postoperative Pain of Thoractomy; Int. J. Med. Sci. vol. 8£3): pp 216-221.
[0086] The anti-inflammatory cytokine, Interleukin-6 (IL6) is assayed as follows: MSD®
Cytokine Assays are used to measure IL6 in 96-well MULTI-ARRAY® or MULTISPOT® plates. The assays employ a sandwich immunoassay format where capture antibodies are coated in a single spot, or in a patterned array, on the bottom of the wells of a MULTIARRAY® or MULTI-SPOT® plate.
[0087] The sample and a solution containing the labeled detection antibody- anti-IL6 antibody labeled with an electrochemiluminescent compound, MSD SULFO-TAG™ label- are added over the course of one or more incubation periods. The IL6 in the sample binds to capture antibody immobilized on the working electrode surface; recruitment of the labeled detection antibody by bound cytokine completes the sandwich. The user adds an MSD read buffer that provides the appropriate chemical environment for electrochemiluminescence and loads the plate into an MSD SECTOR® instrument for analysis. Inside the SECTOR® instrument, a voltage applied to the plate electrodes causes the labels bound to the electrode surface to emit light. The instrument measures intensity of emitted light to provide a quantitative measure of IL6 present in the sample.
EXAMPLES
[0088] EXAMPLE 1 : First in man clinical trial of a peripherally-restricted non-narcotic kappa receptor agonist
[0089] This trial was a phase 2 multi-center, double-randomized, double-blind, placebo- controlled study was conducted to evaluate the analgesic efficacy and safety of intravenous CR845 dosed preoperatively and postoperatively in patients undergoing a laparoscopic hysterectomy. The trial was conducted under an investigational new drug application (IND) filed with the US Food and Drug Administration (FDA).
[0090] This phase 2 trial multi-center, double-randomized, double-blind, placebo- controlled study was conducted in 22 sites in the United States. All clinical procedures were
approved by the relevant Institutional Review Board (IRB) in compliance with the applicable laws and regulations of the US. The study was initiated up to fourteen (14) days preoperatively and the in-hospital period was approximately twenty-four (24) hours for each patient and follow up was conducted within seven (7) days of discharge from the hospital.
[0091] The all-D-tetrapeptide amide, CR845 is a peripherally-restricted kappa-opioid receptor agonist, in Phase 2 of clinical development for the treatment of acute pain. Thus far, CR845 has been shown to have analgesic and morphine-sparing effects in a proof of concept clinical study when administered after surgery (single intravenous dose) (Menzaghi et al., IASP 2010). In addition, CR845 appeared to be better tolerated in comparison to other known kappa agonists, likely due to its limited CNS penetration.
[0092] The aim of this clinical trial was to evaluate the analgesic efficacy and safety of intravenous (IV) CR845 dosed preoperatively and postoperatively in female patients undergoing an elective laparoscopic hysterectomy. Secondary objectives were: 1. To evaluate the efficacy of CR845 compared to placebo in reducing pain following laparoscopic hysterectomy: (a) to determine the time specific visual analog pain score (VAS) difference, summed pain intensity differences over all time periods (SPIDs) and pain relief, etc. and (b) to evaluate the proportion of patents that were randomized to receive preoperative CR845 and received no rescue medication postoperatively, compared to those who received placebo preoperatively and did not receive any rescue medication; and 2. To evaluate the safety and tolerability of CR845.
[0093] This Phase 2, double-randomized, double-blind, placebo-controlled, parallel group study was conducted in approximately 200 female subjects, aged 18 to 65, across 22 US clinical sites. All subjects were administered a 15-minute IV infusion of 0.04 mg/kg CR845 or matching placebo before surgery in a 1: 1 ratio. After surgery and upon reaching a pain intensity baseline level of at least 4 on a 10 cm visual analog scale (VAS), subjects were also re- randomized in a 1: 1 ratio to receive a second IV infusion of either 0.04 mg/kg of CR845 or placebo. All doubly-randomized patients were thereby randomized to receive one of four possible treatment regimens: placebo-placebo, placebo-CR845, CR845-placebo, or CR845- CR845 (See Fig. 1). Pain intensity and pain relief scores were assessed up to 24 hours following
the post-surgery infusion. Patients were allowed IV morphine for rescue at any point during the post-operative period, if requested.
[0094] The main efficacy endpoints were the total morphine consumption in the first 24 hours in patients who were re -randomized in the postoperative period and the efficacy of CR845 in reducing pain intensity including time specific VAS difference; summed pain intensity differences (SPIDs); area under the curve (AUC); pain relief; and the proportion of patients that were randomized to receive preoperative CR845 with no rescue medication postoperatively. The safety endpoints included the incidence of adverse events, physical examination, vital signs, 12- lead ECG, clinical laboratory evaluations, and cumulative fluid balance.
[0095] EXAMPLE 2: Relative Levels of Reduction of Post- Operative Pain (SPIDs)
[0096] Fig. 2 shows the relative levels of reduction of post-operative pain over the first
24 hours after surgery as demonstrated by the summed pain intensity difference (SPID) summed over all of the time points. Patients receiving only placebo showed the least pain reduction and those receiving CR845 both before and after surgery showed the greatest reduction in the SPID pain score (more than twice the reduction over 24 hours as experienced by the patients receiving only placebo). Patients receiving one dose of CR845, whether before or after surgery exhibited an intermediate level of reduction in pain SPID scores (i.e. more relief than seen in patients receiving only placebo, but less than the relief experienced by those patients receiving CR845 before surgery and also after surgery).
[0097] EXAMPLE 2: Relative Levels of Reduction of Post- Operative Pain (PIDs)
[0098] Fig. 3 shows the relative levels of reduction of post-operative pain over the first
24 hours after surgery as demonstrated by the pain intensity difference (PID) at each time point. As shown above for the summed pain intensity difference, patients receiving only placebo showed the least pain reduction and those receiving CR845 both before and after surgery showed the greatest reduction in the SPID pain score (twice the reduction over 24 hours as experienced by the patients receiving only placebo). Patients receiving one dose of CR845, whether before or after surgery exhibited an intermediate level of reduction in pain PID scores (i.e. more relief than seen in patients receiving only placebo, but less than the relief experienced by those patients receiving CR845 before surgery and also after surgery).
[0099] EXAMPLE 3: Morphine Self-administered by the Patients
[00100] Fig 4 shows the amounts of morphine (in milligrams) self administered by the patients in each group: placebo-placebo, placebo-CR845, CR845-placebo, and CR845-CR845 in the interval 2-4 hours, 4-12 hours and 12-24 hours post surgery. Patients receiving only placebo self-administered the most intrathecally delivered morphine (mITT), more than doubling the dose self administered from 2-4 hours during each of the 4-12 hour and 12-24 hour periods. By contrast, those patients receiving two doses of CR845 self-administered the least morphine in each time period.
[00101] EXAMPLE 4: Evaluations of Pain Relief Assessed by Patients
[00102] Fig. 5 shows the evaluations of pain relief as assessed by the patients themselves.
The four patient groups are those receiving pre- and post-operatively respectively:
(a) Placebo-Placebo;
(b) CR845-CR845;
(c) Placebo-CR845; and
(d) CR845-Placebo.
[00103] The Placebo-Placebo group (i.e receiving inactive placebo instead of the peripherally-restricted kappa opioid receptor agonist) showed the lowest pain intensity difference (i.e. the least pain relief) and the group receiving CR845 before and after surgery showed the highest pain intensity difference (i.e. most pain relief) as judged by PID score.
[00104] EXAMPLE 4: Global Evaluations of Pain Relief Assessed by Patients
[00105] Fig. 6 shows the overall evaluations of pain relief as assessed by the patients themselves. The six patient groups are those receiving pre- and post-operatively respectively:
(a) Placebo-Placebo; (71 patients)
(b) CR845-CR845; (20 patients)
(c) CR845-Placebo; (19 patients)
(d) CR845-None; (5 patients)
(e) Placebo-CR845; (71 patients) and
(f) Placebo-None; (11 patients).
[00106] The highest percentage of patients giving an assessment of the overall evaluation of the pain relief as "excellent" were in the CR845 pretreatment groups, i.e. groups (b), (c) and (d). These data also show that groups pre-treated with CR845 were consistently evaluated as very good or excellent by the highest percentage of patients. The above-described clinical data demonstrate that CR845 represents an effective novel therapeutic class useful for pretreatment of postoperative pain and inflammation.
[00107] EXAMPLE 5: Assay of IL6 in patient blood samples
[00108] The anti-inflammatory cytokine, Interleukin-6 (IL6) is assayed using the MSD®
Cytokine Assays to measure IL6 in 96-well MULTI-ARRAY® or MULTISPOT® plates (Meso Scale Discovery, Gaithersburg, MD) according to the manufacturer's instructions. The assays employ a sandwich immunoassay format where capture antibodies are coated in a single spot, or in a patterned array, on the bottom of the wells of a MULTIARRAY® or MULTI-SPOT® plate.
[00109] The serum sample and a solution containing the labeled detection antibody- anti-
IL6 antibody labeled with an electrochemiluminescent compound, MSD SULFO-TAG™ label- are added over the course of one or more incubation periods. The IL6 in the sample binds to capture antibody immobilized on the working electrode surface; recruitment of the labeled detection antibody by bound cytokine completes the sandwich. The user adds an MSD read buffer that provides the appropriate chemical environment for electrochemiluminescence and loads the plate into an MSD SECTOR® instrument for analysis. Inside the SECTOR® instrument, a voltage applied to the plate electrodes causes the labels bound to the electrode surface to emit light. The instrument measures intensity of emitted light to provide a quantitative measure of IL6 present in the sample.
[00110] Calibrators are run in duplicate to generate a standard curve. The standard curve is modeled using least squares fitting algorithms so that signals from samples with known levels of IL6 can be used to calculate the concentration of analyte in the sample. The assays have a wide dynamic range (3-4 logs) which allows accurate quantitation in many samples without the need for dilution. The MSD DISCOVERY WORKBENCH® analysis software utilizes a 4- parameter logistic model (or sigmoidal dose-response) and includes a 1/Y2 weighting function. The weighting function is important because it provides a better fit of data over a wide dynamic range, particularly at the low end of the standard curve.
[00111] EXAMPLE 6: Assay of C-reactive protein in patient blood samples
[00112] The Invitrogen Hu CRP kit is a solid phase sandwich Enzyme Linked-Immuno-
Sorbent Assay (ELISA) useful for the determination of CRP levels in a sample and was used according to the manufacturer's instructions. . Alternatively, CRP levels were determined using the C-Reactive Protein High Sensitivity Test by Roche Diagnostics according to the
manufacturer's instructions.
[00113] Briefly, a highly purified antibody is coated onto the wells of the microtiter strips provided. During the first incubation, standards of known Hu CRP content, controls, and unknown samples were pipetted into the coated wells. After washing, biotinylated second antibody was added. After another washing, Streptavidin-Peroxidase (enzyme) was added. This binds to the biotinylated antibody to complete the four-member sandwich. After a third incubation and washing to remove all the unbound enzyme, a substrate solution was added, which was acted upon by the bound enzyme to produce color. The intensity of this colored product is directly proportional to the concentration of Hu CRP present in the original specimen. Results are shown in Fig. 6. Levels of CRP appeared to be comparable between patients treated with CR845 pre- and post-surgically versus placebo. However, it should be noted that CRP is produced by the liver not by immune cells and so may not be a good marker for surgically induced inflammation.
[00114] EXAMPLE 7: Thirteen-Plex assay of cytokines in patient serum samples
[00115] The Human Cytokine MILLIPLEX MAP assay panel with the Luminex® xMAP® microsphere technology optimized format (Millipore, St. Charles, Missouri) was used to measure serum concentrations of a panel of 13 cytokines: IL-Ιβ, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13, GM-CSF, IFNy, and TNFa were quantified in human serum samples according to the manufacturer's instructions. Samples were serum samples taken at 1 hour, 8 hours and 24 hours post laparoscopic surgery in a Phase lib clinical trial in which subjects were administered CR845 or placebo as shown in figures 6-14.
[00116] The method uses Luminex® proprietary techniques to internally color-code microspheres with two fluorescent dyes. Assays depend on a hundred distinctly colored microsphere sets, each of which is coated with a specific capture antibody. The cytokine in the test sample is captured by the microspheres, and a biotinylated detection antibody is used as detection agent.- The reaction mixture is then incubated with Streptavidin-PE conjugate, the
reporter molecule, to complete the reaction on the surface of each microsphere. The microspheres are then passed rapidly through a laser which excites the internal dyes marking the microsphere set. A second laser excites PE, the fluorescent dye on the reporter molecule. A high-speed digital-signal processor is used to identify each individual microsphere and quantify the result of its bioassay based on fluorescent reporter signals. Multiple results were thus obtained from each sample.
[00117] Changes in cytokine levels were detected in most cases (see Figs 6-14), however, changes in cytokine levels that occurred between the three sampling times or even before 1 hour or after 24 hours post surgery would not have been detected.
[00118] EXAMPLE 8: Adverse events in subjects treated with CR845 or placebo
[00119] Adverse events (nausea, vomiting and pruritus) occurring in the first 24 hours post laparoscopic surgery are shown in Fig. 15. Data are from a Phase lib clinical trial in which subjects were administered CR845 or placebo. Generalized pruritus was distinguished from local pruritus events and shown separately in Fig. 15. Adverse events were lower in all CR845 treated patient groups as compared with placebo treated patients.
[00120] The specifications of each of the U.S. patents, allowed and published patent applications, and the texts of the literature references cited in this specification are herein incorporated by reference in their entireties. In the event that any definition or description contained found in one or more of these references is in conflict with the corresponding definition or description herein, then the definition or description disclosed herein is intended.
[00121] The examples provided herein are for illustration purposes only and are not intended to limit the scope of the invention, the full breadth of which will be readily recognized by those of skill in the art.
Claims
1. A method for reducing kappa opioid receptor-associated inflammation in a mammalian subject, the method comprising administering an effective amount of a peripherally-restricted kappa opioid receptor agonist to the subject.
2. The method according to claim 1, wherein the administering of the peripherally restricted kappa opioid receptor agonist causes a reduction in the level of one or more pro-inflammatory cytokines and/or the increase in an level of one or more anti-inflammatory cytokines in the blood of the subject.
3. The method according to claim 2, wherein the one or more pro-inflammatory cytokines are selected from the group consisting of IL-Ιβ, IL-2, IL-4 IL-6, IL-7, IL-8, IL-12, GM-CSF, TNFa and IFNy.
4. The method according to claim 2, wherein the one or more anti-inflammatory cytokines are selected from the group consisting of IL-5, IL-10 and IL-13.
5. The method according to claim 1, wherein the inflammation is due to an inflammatory disease or condition.
6. The method according to claim 1, wherein the inflammation is due to a medical procedure.
7. The method according to claim 1, wherein the inflammation is due to a physical insult.
8. The method according to claim 5, wherein the inflammatory disease or condition is selected from the group consisting of sinusitis, rheumatoid arthritis tenosynovitis, bursitis, tendonitis, lateral epicondylitis, adhesive capsulitis, osteomyelitis, osteoarthritic inflammation, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ocular inflammation, otitic inflammation and autoimmune inflammation.
9. The method according to claim 6, wherein the inflammation is due to a medical procedure selected from the group consisting of appendectomy, open colorectal surgery, hernia repair, prostatectomy, colonic resection, gastrectomy, splenectomy, colectomy, colostomy,
pelvic laparoscopy, tubal ligation, hysterectomy, vasectomy, cholecystectomy, colonoscopy, cystoscopy, hysteroscopy, cervical and endometrial biopsy.
10. The method according to claim 6, wherein the inflammation is due to a physical insult selected from the group consisting of an abrasion, a cut, a bone fracture, and an open wound.
11. The method according to claim 1, wherein the peripherally-restricted kappa opioid receptor agonist is administered by a route of injection selected from the group consisting of subcutaneous injection, intravenous injection, intraperitoneal injection, intra-articular injection, intramuscular injection and intra-ocular injection.
12. The method according to claim 1, wherein the peripherally restricted kappa opioid receptor agonist comprises a peptide.
13. The method according to claim 2, wherein the peptide comprises at least four D-amino acids.
14. The method according to claim 1, wherein the peripherally restricted kappa opioid receptor agonist comprises a synthetic peptide amide having the formula:
Ri-(V)e-R2
or a stereoisomer, mixture of stereoisomers, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, N-oxide or isomorphic crystalline form thereof;
wherein
Xaai is selected from the group consisting of (A)(A')D-Phe, (A)(A')(a-Me)D-Phe, D-Tyr, D-Tic, D-tert-leucine, D-neopentylglycine, D-phenylglycine, D-homophenylalanine, and P-(E)D-Ala, wherein each (A) and each (Α') are phenyl ring substituents independently selected from the group consisting of -H, -F, -CI, -N02, -CH3, -CF3, -CN, and -CONH2, and wherein each (E) is independently selected from the group consisting of cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, thienyl and thiazolyl;
Xaa2 is selected from the group consisting of (A)(A')D-Phe, 3,4-dichloro-D-Phe, (A)(A')(a-Me)D-Phe, D-lNal, D-2Nal, D-Tyr, (E)D-Ala and D-Trp;
Xaa3 is selected from the group consisting of D-Nle, D-Phe, (E)D-Ala, D-Leu, (a-Me)D-Leu, D-Hle, D-Val, and D-Met;
Xaa4 is selected from the group consisting of (B)2D-Arg, (B)2D-Nar, (B)2D-Har, ζ-(Β)ϋ-Ι¾¾, D-Dap, s-(B)D-Lys, s-(B)2-D-Lys, D-Amf, amidino-D-Amf, y-(B)2D-Dbu, δ-(Β)2α- (B')D-Orn, D-2-amino-3(4-piperidyl)propionic acid, D-2-amino-3(2- aminopyrrolidyl)propionic acid, D-a-amino-P-amidinopropionic acid, a-amino-4- piperidineacetic acid, cis-a,4-diaminocyclohexane acetic acid, trans-a,4- diaminocyclohexaneacetic acid, cis-a-amino-4-methylaminocyclo-hexane acetic acid, trans-a-amino-4-methylaminocyclohexane acetic acid, a-amino-l-amidino-4- piperidineacetic acid, cis-a-amino-4-guanidinocyclohexane acetic acid, and trans-a- amino-4-guanidinocyclohexane acetic acid, wherein each (B) is independently selected from the group consisting of H and Ci-C4 alkyl, and (Β') is H or (a-Me);
W is selected from the group consisting of:
Null, provided that when W is null, Y is N;
-NH-(CH2)b- with b equal to zero, 1, 2, 3, 4, 5, or 6; and
-NH-(CH2)c-0- with c equal to 2, or 3, provided that Y is C;
the moiety
is an optionally substituted 4 to 8-membered heterocyclic ring moiety wherein all ring heteroatoms in said ring moiety are N; wherein Y and Z are each independently C or N; provided that when such ring moiety is a six, seven or eight-membered ring, Y and Z are separated by at least two ring atoms; and provided that when such ring moiety has a single ring heteroatom which is N, then such ring moiety is non-aromatic;
V is Q-C6 alkyl, and e is zero or 1, wherein when e is zero, then V is null and Ri and R2 are directly bonded to the same or different ring atoms;
wherein (i) Ri is selected from the group consisting of -H, -OH, halo, -CF3, -NH2, -COOH, Ci-C6 alkyl, C C6 alkoxy, amidino, C C6 alkyl-substituted amidino, aryl, optionally substituted heterocyclyl, Pro-amide, Pro, Gly, Ala, Val, Leu, He, Lys, Arg, Orn, Ser, Thr,
-CN, -CONH2, -COR', -SO2R', -CONR'R", -NHCOR', OR' and S02NR'R"; wherein said optionally substituted heterocyclyl is optionally singly or doubly substituted with substituents independently selected from the group consisting of C -C alkyl, C -C alkoxy, oxo, -OH, -CI, -F, -NH2, -N02, -CN, -COOH, and amidino; wherein R' and R" are each independently -H, Ci-Cg alkyl, aryl, or heterocyclyl or R' and R" are combined to form a 4- to 8-membered ring, which ring is optionally singly or doubly substituted with substituents independently selected from the group consisting of C1-C6 alkyl, -C1-C6 alkoxy, -OH, -CI, -F, -NH2, -N02, -CN, -COOH and amidino; and R2 is selected from the group consisting of -H, amidino, singly or doubly C C6 alkyl-substituted amidino, -CN, - CONH2, -CONR'R", -NHCOR', -S02NR'R" and -COOH; or
(ii) Ri and R2 taken together can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety which is bonded to a single ring atom of the Y and Z-containing ring moiety; or
(iii) Ri and R2 taken together with a single ring atom of the Y and Z-containing ring moiety can form an optionally substituted 4- to 8-membered heterocyclic ring moiety to form a spiro structure; or
(iv) Ri and R2 taken together with two or more adjacent ring atoms of the Y and Z- containing ring moiety can form an optionally substituted 4- to 9-membered heterocyclic monocyclic or bicyclic ring moiety fused to the Y and Z-containing ring moiety;
wherein each of said optionally substituted 4-, 5-, 6,-, 7-, 8- and 9-membered heterocyclic ring moieties comprising Ri and R2 is optionally singly or doubly substituted with substituents independently selected from the group consisting of Ci-C6 alkyl, C - C6 alkoxy, optionally substituted phenyl, oxo, -OH, -CI, -F, -NH2, -N02, -CN, - COOH, and amidino;
provided that when the Y and Z-containing ring moiety is a six or seven membered ring having a single ring heteroatom and e is zero, then Ri is not -OH, and Ri and R2 are not both -H; and
provided further that when the Y and Z-containing ring moiety is a six membered ring having two ring heteroatoms, both Y and Z are N and W is null, then -(V)eRiR2 is attached to a ring atom other than Z; and if e is zero, then Ri and R2 are not both -H.
The method of claim 14, wherein the moiety:
Ri-(V)e-R2 selected from the group consisting
The method of claim 14, wherein the synthetic peptide amide has the structure:
D-Phe-D-Phe-D-Leu-D-Lys-[ro(4-aminopiperidine-4-carboxylic acid)] -OH.
17. The method of claim 16, wherein the mammalian subject is a human.
18. The method according to claim 1, wherein the peripherally-restricted kappa opioid receptor agonist is a non-narcotic analgesic.
19. The method according to claim 1, wherein the peripherally-restricted kappa opioid receptor agonist is asimadoline (N-[(lS)-2-[(3S)-3-hydroxypyrrolidin-l-yl]-l-phenylethyl]-N- methyl-2,2-diphenylacetamide).
20. The method according to claim 1, wherein the peripherally-restricted kappa opioid receptor agonist is nalfurafine ((2E)-N-[(5a,6P)-17-(cyclopropylmethyl)-3,14-dihydroxy-4,5- epoxymorphinan- 6-yl]-3-(3-furyl)-N-methylacrylamide).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/403,535 US20150150935A1 (en) | 2012-06-05 | 2013-06-05 | Peripheral kappa receptor agonists for reducing pain and inflammation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655731P | 2012-06-05 | 2012-06-05 | |
| US61/655,731 | 2012-06-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2013184794A2 true WO2013184794A2 (en) | 2013-12-12 |
| WO2013184794A3 WO2013184794A3 (en) | 2014-01-30 |
Family
ID=49712832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2013/044302 WO2013184794A2 (en) | 2012-06-05 | 2013-06-05 | Peripheral kappa receptor agonists for reducing pain and inflammation |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20150150935A1 (en) |
| WO (1) | WO2013184794A2 (en) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073443A3 (en) * | 2014-11-05 | 2016-08-11 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for hard tissue pain |
| WO2016181408A2 (en) | 2015-05-11 | 2016-11-17 | Cadila Healthcare Limited | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST |
| CN107098876A (en) * | 2016-02-23 | 2017-08-29 | 江苏恒瑞医药股份有限公司 | Phenylpropionyl amine derivant, its preparation method and its in application pharmaceutically |
| CN108290926A (en) * | 2016-06-07 | 2018-07-17 | 江苏恒瑞医药股份有限公司 | Phenylpropionyl amine derivant, preparation method and its application in medicine |
| CN109563133A (en) * | 2016-09-27 | 2019-04-02 | 四川科伦博泰生物医药股份有限公司 | Multiamide compound and application thereof |
| WO2019109934A1 (en) | 2017-12-06 | 2019-06-13 | 江苏恒瑞医药股份有限公司 | Salt of phenylpropionamide derivative and preparation method therefor |
| CN109879934A (en) * | 2017-12-06 | 2019-06-14 | 江苏恒瑞医药股份有限公司 | A kind of salt and preparation method thereof of phenylpropionyl amine derivant |
| WO2019219019A1 (en) | 2018-05-16 | 2019-11-21 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition of kor receptor agonist |
| US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| US10836771B2 (en) | 2017-03-20 | 2020-11-17 | Forma Therapeutics, Inc. | Compositions for activating pyruvate kinase |
| US11001588B2 (en) | 2018-09-19 | 2021-05-11 | Forma Therapeutics, Inc. | Activating pyruvate kinase R and mutants thereof |
| WO2021093695A1 (en) * | 2019-11-12 | 2021-05-20 | Chengdu Sintanovo Biotechnologv Co., Ltd. | Polypeptide compound, pharmaceutical composition, preparation method and application thereof |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| US11324742B2 (en) | 2018-03-08 | 2022-05-10 | Victoria Link Ltd. | Treatment of demyelinating diseases |
| RU2776749C2 (en) * | 2017-12-06 | 2022-07-26 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Phenyl propionamide derivative salt and its production method |
| WO2023179659A1 (en) * | 2022-03-23 | 2023-09-28 | 江苏恩华药业股份有限公司 | Polyamide compounds, method for preparing same, and medical use thereof |
| US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102664288B1 (en) * | 2018-09-14 | 2024-05-09 | 케러 테라퓨틱스, 인코포레이티드 | Oral formulations of kappa opioid receptor agonists |
| CN111978371B (en) * | 2019-05-22 | 2022-05-13 | 成都诺和晟泰生物科技有限公司 | Polypeptide derivative and application thereof in field of medicine |
| KR20230024419A (en) | 2020-06-25 | 2023-02-20 | 휴먼웰 파마슈티컬 유에스 | Peptides for the treatment of medical disorders |
| CN115043904B (en) * | 2021-03-08 | 2024-07-23 | 成都奥达生物科技有限公司 | Long-acting K opioid receptor agonist |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100075910A1 (en) * | 2006-11-10 | 2010-03-25 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
| US20110212882A1 (en) * | 2006-11-10 | 2011-09-01 | Cara Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0718651B8 (en) * | 2006-11-10 | 2021-05-25 | Cara Therapeutics Inc | synthetic peptide amides |
| US7842662B2 (en) * | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
| US7713937B2 (en) * | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
-
2013
- 2013-06-05 WO PCT/US2013/044302 patent/WO2013184794A2/en active Application Filing
- 2013-06-05 US US14/403,535 patent/US20150150935A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100075910A1 (en) * | 2006-11-10 | 2010-03-25 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
| US20110212882A1 (en) * | 2006-11-10 | 2011-09-01 | Cara Therapeutics, Inc. | Uses of kappa opioid synthetic peptide amides |
Non-Patent Citations (1)
| Title |
|---|
| NEGUS S.S. ET AL.: 'Effects of peripherally restricted k opioid receptor agonists on pain-related stimulation and depression of behavior in rats.' J. PHARMACOL. EXP. THER vol. 340, no. 3, March 2012, pages 501 - 509 & DATABASE PUBMED Database accession no. 22128346 * |
Cited By (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073443A3 (en) * | 2014-11-05 | 2016-08-11 | Cara Therapeutics, Inc. | Peripheral kappa opioid receptor agonists for hard tissue pain |
| US10550150B2 (en) | 2015-05-11 | 2020-02-04 | Cadila Healthcare Limited | Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist |
| WO2016181408A2 (en) | 2015-05-11 | 2016-11-17 | Cadila Healthcare Limited | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST |
| WO2016181408A3 (en) * | 2015-05-11 | 2016-12-22 | Cadila Healthcare Limited | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST |
| EP3294315A2 (en) * | 2015-05-11 | 2018-03-21 | Cadila Healthcare Limited | Novel short-chain peptides as kappa opioid receptors (kor) agonist |
| CN107098876A (en) * | 2016-02-23 | 2017-08-29 | 江苏恒瑞医药股份有限公司 | Phenylpropionyl amine derivant, its preparation method and its in application pharmaceutically |
| CN107098876B (en) * | 2016-02-23 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | Phenyl propionamide derivative, preparation method and medical application thereof |
| EP3466962A4 (en) * | 2016-06-07 | 2020-01-08 | Jiangsu Hengrui Medicine Co., Ltd. | Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof |
| RU2738207C2 (en) * | 2016-06-07 | 2020-12-09 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Phenylpropanamide derivative, a method for production thereof and pharmaceutical use thereof |
| CN114940700A (en) * | 2016-06-07 | 2022-08-26 | 江苏恒瑞医药股份有限公司 | Phenyl propionamide derivative, preparation method and medical application thereof |
| CN108290926B (en) * | 2016-06-07 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | Phenyl propionamide derivative, preparation method and medical application thereof |
| CN108290926A (en) * | 2016-06-07 | 2018-07-17 | 江苏恒瑞医药股份有限公司 | Phenylpropionyl amine derivant, preparation method and its application in medicine |
| CN114349820A (en) * | 2016-06-07 | 2022-04-15 | 江苏恒瑞医药股份有限公司 | Phenyl propionamide derivative, preparation method and medical application thereof |
| AU2017277003B2 (en) * | 2016-06-07 | 2021-01-07 | Jiangsu Hengrui Medicine Co., Ltd. | Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof |
| CN109563133A (en) * | 2016-09-27 | 2019-04-02 | 四川科伦博泰生物医药股份有限公司 | Multiamide compound and application thereof |
| CN109563133B (en) * | 2016-09-27 | 2020-09-11 | 四川科伦博泰生物医药股份有限公司 | Polyamide compound and use thereof |
| EP3521301A4 (en) * | 2016-09-27 | 2020-05-27 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Polyamide compound and use thereof |
| US11084847B2 (en) | 2016-09-27 | 2021-08-10 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Polyamide compound and use thereof |
| US10836771B2 (en) | 2017-03-20 | 2020-11-17 | Forma Therapeutics, Inc. | Compositions for activating pyruvate kinase |
| US11649242B2 (en) | 2017-03-20 | 2023-05-16 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
| US11396513B2 (en) | 2017-03-20 | 2022-07-26 | Forma Therapeutics, Inc. | Compositions for activating pyruvate kinase |
| US12071440B2 (en) | 2017-03-20 | 2024-08-27 | Novo Nordisk Health Care Ag | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
| US11014927B2 (en) | 2017-03-20 | 2021-05-25 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
| RU2776749C2 (en) * | 2017-12-06 | 2022-07-26 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Phenyl propionamide derivative salt and its production method |
| CN111065631A (en) * | 2017-12-06 | 2020-04-24 | 江苏恒瑞医药股份有限公司 | Salt of phenylpropionamide derivative and preparation method thereof |
| WO2019109934A1 (en) | 2017-12-06 | 2019-06-13 | 江苏恒瑞医药股份有限公司 | Salt of phenylpropionamide derivative and preparation method therefor |
| CN109879934A (en) * | 2017-12-06 | 2019-06-14 | 江苏恒瑞医药股份有限公司 | A kind of salt and preparation method thereof of phenylpropionyl amine derivant |
| JP2021505596A (en) * | 2017-12-06 | 2021-02-18 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | Salt of phenylpropionamide derivative and its production method |
| EP3722286A4 (en) * | 2017-12-06 | 2021-08-25 | Jiangsu Hengrui Medicine Co., Ltd. | Salt of phenylpropionamide derivative and preparation method therefor |
| US11180530B2 (en) | 2017-12-06 | 2021-11-23 | Jiangsu Hengrui Medicine Co., Ltd. | Salt of phenylpropionamide derivative and preparation method therefor |
| US11324742B2 (en) | 2018-03-08 | 2022-05-10 | Victoria Link Ltd. | Treatment of demyelinating diseases |
| US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
| WO2019219019A1 (en) | 2018-05-16 | 2019-11-21 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition of kor receptor agonist |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| US11980611B2 (en) | 2018-09-19 | 2024-05-14 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| US11001588B2 (en) | 2018-09-19 | 2021-05-11 | Forma Therapeutics, Inc. | Activating pyruvate kinase R and mutants thereof |
| US11071725B2 (en) | 2018-09-19 | 2021-07-27 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| US11844787B2 (en) | 2018-09-19 | 2023-12-19 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| US12122778B2 (en) | 2019-09-19 | 2024-10-22 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| EP3825322A1 (en) | 2019-11-12 | 2021-05-26 | Chengdu Sintanovo Biotechnology Co., Ltd | Polypeptide compound, pharmaceutical composition, preparation method and application thereof |
| US11643436B2 (en) | 2019-11-12 | 2023-05-09 | Chengdu Sintanovo Biotechnology Co., Ltd. | Polypeptide compound, pharmaceutical composition, preparation method and application thereof |
| WO2021093695A1 (en) * | 2019-11-12 | 2021-05-20 | Chengdu Sintanovo Biotechnologv Co., Ltd. | Polypeptide compound, pharmaceutical composition, preparation method and application thereof |
| US12128035B2 (en) | 2022-03-18 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2023179659A1 (en) * | 2022-03-23 | 2023-09-28 | 江苏恩华药业股份有限公司 | Polyamide compounds, method for preparing same, and medical use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013184794A3 (en) | 2014-01-30 |
| US20150150935A1 (en) | 2015-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150150935A1 (en) | Peripheral kappa receptor agonists for reducing pain and inflammation | |
| US10307463B2 (en) | Method for administering omega-conopeptide | |
| US6362190B2 (en) | Method for treating inflammatory diseases by administering a thrombin inhibitor | |
| JP6279626B2 (en) | Μ opioid receptor agonist analogs of endomorphin | |
| US20130237478A1 (en) | Compositions and methods for treatment of peripheral vascular disease | |
| US20040152745A1 (en) | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors | |
| US20170258766A1 (en) | Angiotensin in treating brain conditions | |
| BRPI0718651B1 (en) | SYNTHETIC PEPTIDE STARCHES | |
| US11154587B2 (en) | Use of peptides to stimulate the immune system | |
| US20080292616A1 (en) | Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same | |
| US20040266851A1 (en) | Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors | |
| US9333233B2 (en) | Methods and compositions for the delayed treatment of stroke | |
| JP2017533967A (en) | Method for treating Huntington's disease using cysteamine composition | |
| US20160199436A1 (en) | Methods and compositions for the treatment of amyotrophic lateral sclerosis | |
| US11879020B2 (en) | Cyclic peptidomimetic for the treatment of neurological disorders | |
| ES2930757T3 (en) | A drug formulation for use in the effective control of acute and/or chronic pain | |
| US20220056075A1 (en) | Method for treating opioid use disorder | |
| US20220168383A1 (en) | Neurotensinergic agonists and methods of using same preventing or treating pain | |
| US20150087605A1 (en) | Compositions and Methods Comprising Carboxylic Acid-Containing Small Molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 14403535 Country of ref document: US |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13800258 Country of ref document: EP Kind code of ref document: A2 |